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Abstract  
Objective: This study sought to investigate clinical, systemic inflammatory and 
patient-reported outcomes comparing non-surgical treatment for periodontal 
disease using exclusively hand instruments, ultrasonic instruments or a 
combination approach. Cost implications of periodontal treatment within a UK 
NHS Dental Hospital are described. 
 
Methods: Fifty-five patients were treated between two studies (randomised 
controlled trial and cohort study) for generalised periodontitis using non-surgical 
periodontal therapy using hand instruments (HI), ultrasonic instruments (UI) or a 
combination approach (CI) with a 90 day follow up. Comparative analysis was 
carried out with respect to instrumentation technique at day 90. Success of 
treatment was objectively assessed against published criteria. Financial 
implications and patient reported outcomes of non-surgical periodontal therapy 
are explored by descriptive analyses. 
 
Results: Non-surgical periodontal treatment was clinically effective across all 
instrumentation approaches at Day 90 follow up (p<0.05). Inter-group 
comparisons demonstrated no clinically significant differences in clinical or 
systemic inflammatory outcomes. UI required less time to complete treatment 
compared to HI, mean difference 21.51 minutes (p<0.003; 95% CI 9.22 to 34.62) 
Objective criteria of success demonstrated a lack of agreement in defining 
successful clinical endpoints. UI had least associated reprocessing and 
maintenance costs. 
 
Conclusions: Clinical and systemic inflammatory outcomes were comparable 
between HI, UI and CI. Comparing HI and UI, UI had a shorter treatment time. UI 
was least costly on a recurring basis. Patients reported satisfaction with 
periodontal treatment. 
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1.1 Introduction 
Periodontitis is a chronic inflammatory disease, associated with the presence of 
bacteria, that affects the support tissues around the teeth (Periodontology, 
2016) and is mediated and modulated by the host immune system (Cunningham 
et al., 2014). The global economic burden of periodontitis is estimated at 54 
billion US dollars per year (Listl et al., 2015) which ranks periodontal disease 
within the top 10 of all (dental or non-dental) global diseases for economic 
burden (Jin et al., 2016, Kassebaum et al., 2014, Marcenes et al., 2013). Modern 
understanding of periodontitis encompasses a complex, multifactorial model of 
non-linear disease initiation and progression (Socransky et al., 1984). 
Periodontitis causes gingival inflammation, loss of connective tissue attachment 
and ultimately supporting alveolar bone – leading to tooth mobility and eventual 
tooth loss if left untreated. Ongoing periodontal disease (encompassing the 
disease processes of gingivitis and periodontitis) results in both a localised and 
systemic rise in multiple inflammatory mediators (Archana et al., 2015). There is 
an emerging bidirectional relationship (Cunningham et al., 2014) between 
systemic diseases and periodontitis. Multiple studies have revealed intriguing 
links between systemic diseases, the periodontal inflammatory process and 
treatment of periodontitis. Further data has emerged that implicates 
periodontal instrumentation in the promotion of systemic bacteraemia, with 
resultant effects upon the systemic inflammatory system (Kinane et al., 2005, 
Zhang et al., 2013, Horliana et al., 2014). This bacteraemia, to a healthy patient 
may be inconsequential. However, to a medically co-morbid individual, such an 
increase in inflammatory markers could potentially have negative effects upon 
general health. The corner stone of effective periodontal treatment is non-
surgical root surface instrumentation. Non-surgical periodontal therapy using 
ultrasonic scalers and/or hand instruments has proven effective in reducing 
microbial burden, resolving local inflammation and creating a clinical condition 
compatible with periodontal health (Keestra et al., 2015). Side effects of non- 
surgical treatment include gingival recession and tooth sensitivity (Lang and 
Lindhe, 2015). Periodontal instrumentation may also result in bacteraemia and 
systemic inflammation. Within the context of an aging population, the proposed 
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links between periodontitis, systemic disease and systemic inflammation 
highlights a need to investigate the systemic effects of periodontal treatment. 
  
1.2 Epidemiology of Periodontitis 
Periodontal disease is one of the most common chronic conditions of the human 
population worldwide. The 2009 UK Adult Dental Health Survey demonstrated 
around 37% of the UK adult population suffer from moderate periodontitis, with 
8% of the population having the advanced form of the disease. Worldwide, it is 
reported approximately 11% of adults suffer from severe periodontitis (Bernabe 
et al., 2020). In order to gather and monitor epidemiologic data across multiple 
countries, the WHO developed and introduced the Community Periodontal Index 
(CPI) in 1982 (Ainamo et al., 1982). This scale was applied to sextants of the 
dentition and categories (from 0-4) denoted the severity of the periodontal 
disease process. A CPI of 0 indicates gingival health with no bleeding on probing 
and no increased periodontal probing depths; 2 indicated gingival bleeding and 
presence of calculus; 3 indicated shallow periodontal pockets (4-5mm) and 4 
indicated deep periodontal pockets (≥6mm). This assessment system later came 
under scrutiny (Baelum and Papapanou, 1996) due to its inability to yield a 
sufficiently detailed estimate of periodontal disease severity and its tendency to 
summarize periodontal disease at the subject level. The CPI scale later inspired 
the development of the Basic Periodontal Examination (BPE), developed by the 
British Society of Periodontology as a routine periodontal health screening tool, 
initially adopted in 1986 in the United Kingdom. 
 
Periodontal disease prevalence is affected by multiple factors. Data 
demonstrates periodontal disease prevalence and severity affecting older age 
groups to a greater degree than younger populations (Petersen, 2003). A study 
(Drury et al., 1999) examining data gathered during the US National Health and 
Nutrition Examination Survey (NHANES III) between the years 1988-1994 
highlighted socioeconomic status and ethnicity as having statistically significant 
effects upon periodontal disease prevalence. 14,000+ subjects were assessed. 
Disparities in prevalence of gingivitis (ranging from 45.7% in high socioeconomic 
status to 63.4% in low socioeconomic status) and periodontal loss of attachment 
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of 4mm or more (20.6% in high socioeconomic status to 33.3% in low 
socioeconomic status) were found. An update to the NHANES study published in 
2015 (Eke et al., 2015) (which used the more accurate method of 6 point probing 
on each tooth) showed consistent evidence that periodontal disease occurred 
with comparative high frequency in low-income and older individuals, with an 
overall 46% of the US population affected by periodontal disease and prevalence 
varying two fold between low and high socioeconomic classes. A later 2013 study 
(Buchwald et al., 2013) of a Pomeranian population of 2566 subjects 
corroborated these findings - low education and low income were statistically 
significant in relation to progression of mean clinical attachment loss (p < 0.01 
and p = 0.046 respectively).  
 
Further identified factors in the prevalence of periodontal disease are those of 
race and geographical location. Data from the aforementioned NHANES III study 
update identified periodontitis prevalence being highest in Hispanics (63.5%) and 
non-Hispanic blacks (59.1%) followed by non-Hispanic Asian Americans (50%) and 
lowest in non-Hispanic whites (40.8%) (Eke et al., 2015). Further variation was 
shown in a Tanzanian population (Baelum et al., 1986) with less than 35% of all 
surfaces assessed exhibiting loss of attachment ≥4mm and less than 10% of 
surfaces having attachment loss exceeding 6mm. A 2003 Swedish cross sectional 
survey, repeated over a period of 30 years, demonstrated 28% of subjects having 
less than one third of root length horizontal bone loss with 11% experiencing 
severe (more than one third of root length) alveolar bone loss (Hugoson et al., 
2008) and an evident trend for decreasing prevalence of periodontal disease 
over time – reaching its minimum at the last time point. More locally, the 2009 
UK Adult Dental Health Survey identified only 17% of dentate adults had no 
evidence of periodontal disease in England, Wales and Northern Ireland (Steele 
et al., 2012). One of the most impressive periodontal disease data libraries, 
grouped by geographic location, is the Periodontal Country Profiles database, 
held by the World Health Organisation, most recently updated in December 2017 
(Organization., 2005. Accessed September 2019. Available 
from https://www5.dent.niigata-u.ac.jp/~prevent/perio/contents.html). From 
this database, it is reported that periodontal disease has an approximate 
prevalence (in 35-44 year olds) ranging from 60% in the USA, 75% in the UK to a 
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reported 28% in Brazil and approximately 10% in Saudi Arabia. This reported 
extreme variation in prevalence is potentially due to insufficient available data 
or may indeed be a true reflection of influence of geographic/race upon disease 
prevalence. Collectively, these data suggest notable differences in periodontal 
disease susceptibility between different populations across the globe. Such 
reported variations in prevalence of periodontal disease may be due to a variety 
of factors including: bias, varying classification methods of disease status, 
number of teeth examined and sample size discrepancies.  
 
1.3 Aetiopathogenesis of Periodontitis 
1.3.1 Pathogenesis 
Gingivitis is a reversible condition, with negligible consequences to the 
periodontium (Axelsson and Lindhe, 1981a, Pihlstrom et al., 2005). Gingivitis is a 
‘non-specific inflammatory condition that is the result of sustained plaque 
biofilm accumulation at and apical to the gingival margin’(Murakami et al., 
2018). Following accumulation of dental plaque around the cervical aspect of 
the tooth, changes within the gingival tissues are observed. In sequence: 
increased gingival crevicular fluid exudation; infiltration of gingival connective 
tissue with numerous macrophages and lymphocytes; followed by a 
predominance of plasma cells and finally collagen depletion has been observed 
(Lindhe et al., 1980). Clinical signs of gingivitis include: redness, swelling, 
oedema, increased gingival crevicular exudate and bleeding on probing. 
Gingivitis has been identified to be a necessary pre-requisite for the 
development of periodontal disease through a variety of longitudinal studies. A 
classic study by Loe et al carried out on Sri Lankan tea workers (Loe et al., 1986) 
identified three distinct patterns of periodontal disease – with all subjects that 
progressed to periodontal disease having evidence of gingivitis. Further studies 
(Ramseier et al., 2017, Schatzle et al., 2003, Clerehugh et al., 1995) continued 
to consistently demonstrate sites developing periodontitis were preceded by 
clinical gingivitis. Interestingly, within a particular cohort of patients, gingivitis 
does not appear to progress to periodontitis – despite prolonged plaque 
accumulation and associated inflammation (Baelum et al., 1986, Loe et al., 
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1986). This phenomenon was foreseen by Lindhe’s earlier studies in the beagle 
dog as progression to periodontitis was not consistent following ligature-induced-
plaque-related gingivitis (Lindhe et al., 1973). The collective conclusions of 
these studies would imply that plaque induced gingivitis alone is not sufficient to 
initiate the progression of destructive periodontitis – thus other factors must 
affect the condition (such as host related or environmental factors).  
 
In approximately 80% of patients, untreated gingivitis will progress to 
destructive periodontal disease. Following on from the collagen depletion seen 
in the established gingivitis lesion (Page and Schroeder, 1976), the inflammatory 
cell infiltrate continues to develop and with apical migration of the junctional 
epithelium, the characteristic threshold of periodontitis is reached – the 
substitution of the junctional epithelium for pocket epithelium. An increase in 
the magnitude of the inflammatory cell infiltrate continues with concurrent loss 
of connective tissue and supporting alveolar bone. If left untreated in this state, 
the microbial community and inflammatory response will be maintained and 
develop (albeit at varying rates within populations (Baelum et al., 1986))– with 
progressive mobility of the involved tooth and given time and left untreated, its 
eventual loss (Giargia and Lindhe, 1997).  
 
1.3.2 Aetiology – Bacterial Plaque  
Within seconds of performing oral hygiene, a layer of salivary proteins 
selectively adsorbs to enamel and oral mucosa to form a thin layer known as the 
salivary pellicle (Mandel, 1987). This layer is on average 17nm thick (Zhang et 
al., 2016) and infers beneficial effects such as lubrication, nutrient 
decomposition and remineralization of dental hard tissues. This layer is 
understood to affect the charge of the surface, thus promoting bacterial 
accumulation and adhesion (Gibbons and Houte, 1975). Historic work (Ritz, 
1967, Frank and Brendel, 1966) identified Streptococci strains (facultative Gram-
positive cocci) as being early colonisers upon the acquired pellicle, thus 
initiating the formation of dental plaque. This theory was later corroborated by 
work by Lai and Listgarten who found a strain of Streptococcus had directly 
attached to the salivary pellicle at the base of the developing dental plaque (Lai 
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et al., 1975) and a distinct columnar arrangement was evident in supragingival 
plaque (Listgarten et al., 1975). Modern techniques have established each site 
on a tooth with plaque accumulation houses approximately 30 different species 
of bacteria (Aas et al., 2005), with an individual having over 400 species residing 
within the periodontal tissues (Dewhirst et al., 2010b). It is thought 
approximately one third of bacterial phylotypes within the oral cavity are still to 
be cultured and identified (Thompson et al., 2015).  
 
Dental plaque itself is defined as a ‘community of microorganisms found on a 
tooth surface, embedded in a matrix of polymers of host and bacterial origin’ 
(Marsh, 2004). The formation of a biofilm community infers numerous benefits to 
the bacteria within, compared to existence as a single bacterium. Firstly, 
members are less susceptible to destruction by antimicrobial agents. 
Communication and cooperation between micro-organisms is facilitated through 
Quorum Sensing – the regulation of gene expression through accumulation of 
signalling compounds that mediate intercellular communications (Solano et al., 
2014). This process aids regulation of bacterial populations and sharing of 
genetic data, ensuring promotion of certain species to propagate the 
community. Biofilms are therefore well organised, physically attached structures 
comprised of potentially disease-causing bacteria. Thus, effective treatments for 
periodontal disease focus on the removal of the source of pathogenic bacteria – 
the biofilm. 
 
Following the discovery of early colonisers adhering to the tooth surface, it was 
later confirmed that progression of the bacterial community is reliant upon 
bacteria-bacteria adhesion mechanisms (Vickerman and Jones, 1995). As more 
species of bacteria join the community, it is believed anaerobic conditions 
eventually predominate. The community develops towards one less conducive to 
periodontal health with distinct compositional variations in the members of the 
bacterial community (Tanner et al., 1979, Slots, 1977). This occurs concurrently 
with the formation of a deepened periodontal pocket and the subgingival 
bacterial niche. As quantity of bacteria increases, so does severity of 
inflammation and periodontal pocket formation. This led to the popular theory 
of the ‘non-specific plaque hypothesis’ (Theilade, 1986) – with no acute 
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discrimination between specific bacterial organisms in the disease process and 
the belief volume of plaque alone was the most significant aetiological factor in 
periodontal disease initiation and progression. 
 
Continued development within the subgingival environment occurs through a 
process of successive adhesion of groups of micro-organisms - with associations 
with each other and the ability to promote the adhesion of the subsequent 
micro-organism group. These associations were quantified by Socransky within 
‘bacterial complexes’ (Socransky et al., 1998). In this study, over 13,000 
subgingival plaque samples were analysed and complexes of bacteria that were 
found in co-existence were assigned colours – green, purple, yellow, orange and 
red. Bacteria in the red (Porphyromonas Gingivalis, Tannerella Forsythia and 
Treponema Denticola) and orange complexes had strong relationships with 
increasing periodontal pocket depths and bleeding on probing. Furthermore, 
sites with no bacteria from the red complex showed evidence of the shallowest 
mean pocket depth compared to sites with all three red complex bacteria 
showing the deepest pockets. These findings question the theory of the ‘non-
specific plaque hypothesis’, being more in favour of the ‘specific plaque 
hypothesis’ (Loesche, 1992) - the assumption that the presence of specific 
bacteria is indicative of disease state. 
 
The ‘specific plaque hypothesis’ has evolved over recent years, as anomalies in 
periodontal microbiology became apparent that could not be explained with this 
model. Firstly, the red complex bacteria Porphyromonas gingivalis has been 
shown to be present in cases of oral health (Ximenez-Fyvie et al., 2000, Diaz et 
al., 2006), albeit in relatively low numbers – thus casting doubt on the 
hypothesis of ‘red complex’ bacteria being exclusive to diseased sites. Newly 
recognised micro-organisms, beyond that of the ‘red complex’, have shown very 
robust association with disease (Griffen et al., 2012). Modern methods of 16S 
PCR amplification have also prompted questioning of the assumption of gram-
negative bacteria predominating in periodontal disease by demonstrating gram-
positive anaerobic cocci Peptostreptococci species in far greater numbers than 
those of gram-negative anaerobes commonly associated with periodontal disease 
(Kumar et al., 2005, Dewhirst et al., 2010a). It is therefore becoming more 
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compelling to consider an overall change in the pre-existing microbiome as part 
of a series of processes in the initiation and progression of periodontitis. These 
concepts were encapsulated in the ‘ecological plaque hypothesis’ – coined by 
Marsh in 1994 (Marsh, 1994). Specifically, this theory discusses changes in the 
environment (such as pH, temperature, osmotic pressure and availability of 
nutrients) resulting in enhanced expression of virulence factors from particular 
putative pathogens, to the detriment of competing bacterial species. Coupled 
with an aberrant host response, this could help explain the pathogenesis of 
periodontitis. In the contemporary literature, the term ‘dysbiosis’ has been used 
to allude to such changes in resident microorganism communities, leading to a 
relative imbalance with associated disease initiation. 
 
A recent theory of periodontal disease progression is the ‘keystone pathogen 
theory’ first described by Hajishengallis (Hajishengallis et al., 2012). This theory 
discusses the concept of the presence of certain microorganisms (specifically in 
low numbers) causing disproportionate effects within the microbiome leading to 
subsequent initiation and propagation of periodontal disease. Specifically, it is 
suggested that P. gingivalis may be a ‘keystone pathogen’ due to its ability to 
both subvert and alter the innate immune response – leading to significant 
environmental change and alteration of growth and development of the biofilm 
as a whole (Hajishengallis et al., 2012) within a murine model. Interestingly, 
(again within a murine model) this same author has shown that even a small 
number of P. gingivalis inoculation alone is capable of inducing periodontitis 
through a significant ‘growth enhancing effect’ in an otherwise healthy 
commensal oral microflora. This particular study also provided further evidence 
of the importance of the complement pathway in periodontitis disease 
development – specifically C3a and C5a (Hajishengallis et al., 2011) and the 
ability of P. gingivalis to modulate this mechanism at the expense of leukocyte 
killing capacity. Periodontitis associated bacteria express numerous virulence 
factors: leukotoxin production, collagenases, endotoxin and induction of 
cytokine production from macrophages, among others (Haffajee and Socransky, 
1994) that have been shown to cause both direct and indirect damage to the 
periodontal tissues.   
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1.3.3  Aetiology – Host response 
It has been argued that the host inflammatory response is both significant and 
instrumental in the initiation and progression of periodontal disease.  
 
The innate immune response includes physical barriers to bacterial infection 
including junctional epithelium, activation of the complement cascade (which 
contributes to both innate and adaptive immune responses), migration of 
leukocytes and phagocytosis. Specific regions identified with leukocyte 
infiltration include the junctional epithelium and the adjacent connective 
tissues (Zadeh et al., 1999). It has been shown that there is a constant level of 
‘immune surveillance’ present in the periodontium – even in apparent clinical 
health (Brecx et al., 1987). Bacterial biofilms present in periodontal disease are 
resistant to the process of phagocytosis (Thurlow et al., 2011, Leid et al., 2005). 
Furthermore, the biofilm also reduces interaction of bacteria with antigen 
presenting cells, thus reducing the potential efficacy of the adaptive immune 
response (Ebersole et al., 2017). Initial inflammation is dominated by 
neutrophils, with macrophages increasing in numbers after 24-48 hours (Ali et 
al., 2011). In an apparently frustrated attempt to address the bacterial biofilm, 
neutrophils perform ‘netosis’, with the release of elastases, hypochlorous acid 
and cathepsins. These are toxic to both bacterial and host cells of the 
periodontium. Of note, cathepsin K is particularly efficient in destruction of 
bone (Wen et al., 2016). Macrophages also play a key role and recognise 
bacterial components through their Toll-like receptors, which can trigger the 
innate response and bridge the gap between adaptive and innate immune 
responses. Macrophages can phagocytose bacteria and then through antigen 
processing and presentation activate antigen specific T cells. The activated T 
helper cells provide assistance to B cells to generate specific antibodies 
(Albandar et al., 2001). These antibodies have a variety of functions including 
opsonization and occupation of the specific pathogen’s active receptor 
(Xynogala et al., 2009). Analysing antibody production (for example IgG levels 
specific to certain pathogens) can provide evidence as to which microorganisms 
are responsible for the host reaction. This is achievable by immune-
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checkerboard methods and have shown promise in linking clinical signs of 
disease with specific periodontal pathogens (Offenbacher et al., 2008). 
 
Following the immune and inflammatory responses, loss of connective tissue and 
periodontal tissue destruction is the culmination of a variety of processes, still 
under investigation which include: inadvertent destruction of connective tissue 
by polymorphonuclear leukocyte enzyme release; lipopolysaccharide directly 
stimulating osteoclastic activity (Lino and Hopps, 1984); cytokine promotion of 
tissue destruction by various means (Graves, 2008) and the action of matrix 
metalloproteinases (Nagase, 1997), released from a variety of cell types.  
 
Alongside the local immune response, a simultaneous systemic inflammatory 
response is evident in periodontitis. A reliable, albeit nonspecific systemic 
marker of the acute phase of the inflammatory response is that of C-reactive 
protein (CRP). CRP is a plasma protein whose presence within serum is indicative 
of ongoing inflammation (Black et al., 2004). Elevated CRP (Podzimek et al., 
2015) associates with the severity of periodontal disease, with highest levels 
found in patents with the aggressive form of periodontitis. A mean CRP of 
2.28mg/L was identified in an aggressive periodontitis group studied. This level 
is in keeping with similar studies within the literature (Salzberg et al., 2006, 
Gani et al., 2009). Interestingly, it also reported that pre-treatment CRP levels 
within periodontitis affected populations differ according to ethnicity. This is 
evidenced in the mean values of CRP ranging from 1.1mg/L within a Caucasian 
American population (Salzberg et al., 2006) to as high as 7.49mg/l within an 
Indian population (Chopra et al., 2012).  From a clinical perspective, bleeding on 
probing index has been shown to be a more reliable predictor of CRP levels 
compared to pocket depth index in the studied population. The consensus 
finding within the literature is of patients with more clinically severe 
periodontitis presenting with increased serum levels of CRP, compared to both 
unaffected control populations and patients with less severe periodontal disease 
(Gomes-Filho et al., 2011, Ebersole et al., 1997, Bansal et al., 2014, Kumar et 
al., 2013). 
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1.3.4  Factors Influencing Aetiology of Periodontitis 
Alongside the microbiome and host response, smoking and diabetes significantly 
impact periodontitis. It has been established that subjects who smoke have 
deeper mean probing depths (Bergstrom and Eliasson, 1987), a greater degree of 
attachment loss (Haffajee and Socransky, 2001), higher levels of loss of 
supporting alveolar bone (Bergstrom et al., 1991, Baljoon, 2005), more tooth 
loss (Mai et al., 2013), more involvement of furcation regions (Mullally and 
Linden, 1996) and as a result of vasoconstriction – less gingivitis and bleeding on 
probing (Preber and Bergstrom, 1986, Haffajee and Socransky, 2001). A 
contemporary systematic review (Leite et al., 2018) revealed a categorically 
increased risk for developing periodontitis of between 1.3 and 3.0 (relative risk) 
for patients who  smoke. A dose-dependant effect has been reported (Bergstrom 
et al., 2000). Tobacco smoking is therefore a highly significant confounder for 
the initiation and progression of periodontal disease. 
 
Diabetic control has been implicated in the magnitude of the periodontal disease 
process. Diabetes is a significant factor in accelerated loss of clinical attachment 
(Grossi and Genco, 1998, Taylor et al., 1996, Salvi et al., 2008), independent of 
other risk factors for periodontal disease. Furthermore, diabetic control (as 
measured by HbA1c) is of importance – poor diabetic control is associated with 
both higher bleeding on probing scores and number of pockets ≥5mm (Lim et al., 
2007). The specific causative pathways explaining this relationship are currently 
under investigation. There is now emerging evidence of a ‘two-way’ relationship 
between diabetes and periodontitis. Besides the accepted relationship between 
poor diabetic control and periodontitis severity, it has been suggested the 
periodontitis disease process itself may negatively affect diabetic control 
(Preshaw et al., 2012, Taylor, 2001, D'aiuto et al., 2018).  
 
1.4 Measuring Periodontal Health and Disease  
Within a clinical context, periodontal disease is detected and diagnosed initially 
by periodontal probing. As periodontal disease progresses, apical migration of 
junctional epithelium results in formation of a ‘periodontal pocket’ which is 
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detectable by manual probing of the region. Periodontal probing is performed by 
placing the end of the probe in the gingival sulcus and applying 0.2N-0.5N of 
force in an apical direction, until the probe meets resistance. With increased 
severity of periodontal disease, an increase in periodontal probing depth is 
typically observed. This is a result of physical migration of the base of the 
pocket epithelium but also a reduction in tissue resistance as connective tissue 
is lost in late stage periodontal disease (Caton et al., 1981). Probing depth and 
the extent of tissue penetration has been shown to be related to ‘thickness of 
probe, pressure applied, contour of the tooth surface, degree of inflammatory 
cell infiltrate and accompanying loss of collagen fibres’ (Listgarten, 1980). 
Therefore, inherent inaccuracies and error with this method of assessment have 
been noted (Grossi et al., 1996). This prompted the development of an 
electronic probe capable of applying a constant force. Unfortunately this 
technology was demonstrated to suffer from error in a systematic review (Silva-
Boghossian et al., 2008). Thus, it is essential for robust training to be provided 
in periodontal probing techniques to ensure reliability in probing measurements 
(Hill et al., 2006) and an error of 1mm in probing depth (either overestimation 
or underestimation) has been widely accepted by the periodontal scientific 
community. 
 
To combine the multiple clinical parameters of periodontal disease progression 
into a single entity and estimate the inflammatory burden of periodontitis, 
Nesse et al (Nesse et al., 2008) introduced the concept of ‘PISA’ (Periodontal 
Inflamed Surface Area) – following on from ALSA (Attachment Loss Surface Area) 
work by Hujoel (Hujoel et al., 2001). This single value aims to provide an 
indicator of the volume of inflamed tissue involved in periodontitis and offer a 
clinically relevant combined indicator of disease status. Calculating PISA is a 
seven-step process and involves reference to root surface area, clinical 
attachment loss, bleeding on probing and recession measurements. PISA is 
calculated for each tooth in turn and then combined to provide an overall value 
for inflamed surface area for the whole mouth. Values for PISA for a 
periodontally healthy patient and a patient with generalised severe periodontal 
disease reside around 28.6mm2 and 3704.2mm2 respectively (Nesse et al., 2008). 
Values of PISA have been shown to be a strong predictor of periodontitis 
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presence – with a sensitivity of 98% and a specificity of 100% (Leira et al., 2018). 
Further, lower quality evidence corroborates these finding with a post-hoc 
analysis of another study’s subject cohort (Park et al., 2017). Association 
between PISA and cytokine concentration in gingival crevicular fluid was 
observed in a convenience sample of a small case control study (Govindarajan et 
al., 2015). Further well-designed trials would strengthen the reliability of PISA 
as a measurement tool for both periodontal disease and an indicator of 
periodontitis’ contribution to systemic inflammatory burden. 
 
There are limitations of PISA aside from accepted measurement errors of CAL 
and PPD. Integral values for root surface area were derived from a meta-analysis 
of average root surface areas combining 22 studies – analysing 4730 root surface 
area measurements (Hujoel, 1994). In this study, significant heterogeneity 
between studies was noted and a variety of biases were suspected. For example, 
‘non-normal’ teeth (ie fused roots) were excluded in some studies and multiple 
sources of potential measurement error in root surface area estimation were 
present. Therefore, validity of a meta-analysis of these measurements could 
legitimately be questioned. Extrapolating this data into the quantification of 
PISA may therefore be flawed and misleading. A further potential issue with PISA 
is that inflammatory infiltrate present around a tooth suffering periodontal 
disease will inevitably extend further than the immediate area of the root 
surface (Lang and Bartold, 2018). This therefore may lead to an underestimation 
of the actual inflamed volume of tissue. Another limitation of PISA relates to 
patients who smoke. The calculation of PISA includes taking account of bleeding 
on probing values, which may partially be masked in patients who smoke 
(Bergstrom and Eliasson, 1987) thus affecting PISA values. However, smoking 
status is shown to positively correlate with overall PISA value (Park et al., 2017). 
Finally, cases with gingival overgrowth prove challenging for PISA calculation – as 
noted by the authors (Nesse et al., 2008). Interestingly, values for PISA are also 
notably absent in the most recent classification of periodontal disease 
(Papapanou et al., 2018). 
 
As a supplement to clinical examination of the periodontal tissues, radiographs 
are a valuable detection method of the periodontal disease process. It has been 
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shown that specific features of diagnostic interest such as furcation 
involvement, periodontal ligament space widening, percentage of remaining 
bone support and periapical periodontitis are only evident to the clinician 
through radiographic examination (Tugnait et al., 2000). The diagnosis of 
periodontitis is primarily by clinical examination and probing; however, 
radiographs serve as a very useful adjunct for guiding periodontal treatment 
planning decisions (Corbet et al., 2009).  
 
1.5 Periodontal Treatment Techniques 
Fundamentally, the treatment for periodontitis relates to risk factor control and 
to the reduction of bacterial load within the oral cavity. The goal being to 
reduce the microbial burden both quantitatively and qualitatively to a level 
more conducive to health. Self-performed plaque control by the patient is an 
integral aspect of maintaining periodontal health which underpins all theories of 
management of periodontal disease (Lindhe et al., 1984). Non-surgical 
periodontal therapy using ultrasonic scalers and/or hand instruments has proven 
effective in reducing microbial burden, resolving local inflammation and 
creating a clinical condition compatible with periodontal health (Keestra et al., 
2015). Further therapies exist within the literature including: subgingival 
irrigation (Greenstein, 1987), host modulation therapy (Oringer, 2002), 
antimicrobial therapy (Slots and Rams, 1990) and local antimicrobial therapies 
(Kinane, 2000). The modality with the largest volume of compelling evidence for 
effective outcomes remains that of non-surgical periodontal therapy using 
ultrasonic scalers and/or hand instruments (Cobb, 1996). The fact that success 
of periodontal therapy hinges on removal of deposits from the root surface 
underpins the effectiveness of mechanical means of deposit removal (Lindhe et 
al., 1982, Badersten et al., 1981). 
 
In the historic literature, an objective of non-surgical periodontal therapy was 
that of ‘scaling and root planing’. This consisted of using principally hand 
instruments, with relatively significant force, to remove all subgingival calculus 
and ‘contaminated root cementum’ – leaving a ‘glass-like’ smooth root surface. 
This technique was practiced widely until research into endotoxin and bacterial 
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biproduct adherence to root surface surfaced. An initial in vitro study (Nakib et 
al., 1982) demonstrated endotoxin on extracted teeth showed minimal 
penetration into dentine/cementum and was very loosely adherent –casting 
doubt on the previously held belief aggressive root planing was a requirement 
for successful therapy. A subsequent in vivo study (Mombelli et al., 1995) 
confirmed successful clinical outcomes from non-surgical periodontal therapy 
could be obtained by avoiding aggressive root planing and only incomplete 
calculus removal. A further study demonstrated favourable cellular attachment 
to disinfected dental calculus (Listgarten and Ellegaard, 1973). Therefore, it has 
now been established that calculus is a plaque retentive factor however its 
complete removal is not necessary to achieve favourable outcomes, similarly, 
aggressive root planing with the intention of removal of root cementum is not 
required for favourable outcomes. Complete removal of calculus in pockets 
>5mm is uncommon, even in specialist hands (Brayer et al., 1989). However 
small deposits of residual calculus have been shown not to negatively affect 
success rates of non-surgical periodontal treatment (Brayer et al., 1989, 
Waerhaug, 1978).  
 
1.5.1 Hand Instrumentation 
Hand instrumentation for the treatment of periodontal disease consists of 
mechanically removing plaque and calculus deposits from the root surface, 
located within a periodontal pocket, using a specially designed curette. 
Advantages of hand instrumentation conventionally include: greater tactile 
feedback, no production of aerosols and close adaptation to specific sites. 
Suggested limitations of hand instrumentation include the requirements for 
regular instrument sharpening (Rees et al., 1999), operator fatigue, greater 
treatment time and potential trauma to adjacent soft tissues. A wide body of 
evidence confirms favourable outcomes in relation to resolution of clinical 
parameters of periodontal disease for hand instrumentation (Badersten et al., 
1987, Ramfjord et al., 1987, Lindhe et al., 1984, Kaldahl et al., 1996). There is 
also evidence that hand instruments may be effective as a final technique, 
following use of powered instruments, in order to achieve the smoothest root 
surface possible (Ruppert et al., 2002).  
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1.5.2  Ultrasonic Instrumentation  
Ultrasonic instrumentation is a subset of ‘powered instrumentation techniques’ 
and relate to the removal of plaque and calculus from the root surface using a 
rapidly vibrating metallic tip connected to a water irrigation system (water may 
be substituted for a variety of solutions) to keep the tip cool and flush debris 
from the operation site. There are two categories of ultrasonic scaler – 
piezoelectric and magnetostrictive. There is currently no evidence supporting 
superior clinical results of one type of ultrasonic scaler. It has been reported 
that piezoelectric devices cause a greater degree of damage to the root surface, 
compared to magnetostrictive (Busslinger et al., 2001). Purported advantages of 
ultrasonic instrumentation include: acoustic streaming, less damage to root 
surface, microcavitation, flushing effects, better access to furcations (Clifford et 
al., 1999) and improved operator comfort (Obeid et al., 2004). Limitations of 
ultrasonic scalers include: production of aerosol, less tactile feedback and 
patient sensitivity from water spray. Technology within the field of ultrasonic 
instrumentation has developed through introduction of specialised tip designs 
(which aid in access to furcations or deep, narrow pockets) and operator 
comfort through patented on/off procedures through the use of a wireless foot 
pedal.  
 
1.5.3  Hand Instrumentation vs Ultrasonic Instrumentation 
Hand instrumentation and ultrasonic instrumentation have been compared 
through a variety of measures. Numerous studies have demonstrated equal 
efficacy in probing depth reduction, clinical attachment gain (Obeid et al., 
2004, Krishna and De Stefano, 2016), bleeding on probing reduction (Badersten 
et al., 1981, Oosterwaal et al., 1987), plaque removal ability (Thornton and 
Garnick, 1982) and reduction of red complex bacteria (Ioannou et al., 2009). 
Superiority of ultrasonic scalers has been suggested in the treatment of 
furcations (Leon and Vogel, 1987) in an in vivo study of 33 furcation involved 
molar teeth – in particular Class II and Class III furcations showed superior 
outcomes with the use of ultrasonic instrumentation. The most recent 
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systematic review of the topic of efficacy of ultrasonics compared to hand 
instruments (Tunkel et al., 2002) analysed 27 articles and reported no significant 
differences between ultrasonic and manual instrumentation techniques relating 
to clinical parameters of success for periodontal treatment or frequency of 
adverse effects. Meta-analysis was not possible due to heterogeneity of studies. 
A significant finding was of ultrasonic treatment taking less time than hand 
instrumentation (P=0.0002, 95% CI 0.39-1.37). The conclusion of this review 
stated ‘the available data do not indicate a difference between ultrasonic/sonic 
and manual debridement in the treatment of chronic periodontitis for single-
rooted teeth; however, the evidence for this is not very strong.’ The authors 
suggested a need for further research into the efficacy of ultrasonics particularly 
in multirooted teeth. Therefore, current evidence would suggest that either 
hand instruments or ultrasonic instruments might effectively be used for non-
surgical periodontal treatment. In reality, many operators use a combination of 
both.  
 
1.6 Defining Success In Periodontal Treatment 
Determining absolute success following non-surgical periodontal therapy can be 
a challenging endeavour. A variety of clinical outcome measures are reported, 
including changes in plaque percentage, bleeding on probing, periodontal 
probing depth and clinical attachment level. Each of these measures are usually 
initially evaluated three months post non-surgical therapy (Cobb, 1996). 
Conclusions can then be inferred as to the success or failure of therapy. It is 
important to note that any improvements in the patient’s periodontal state can 
soon be reversed within a few weeks if self-performed plaque control becomes 
inadequate (Magnusson et al., 1984).  
 
There are challenges in defining success at a patient level, and further 
challenges when considering success at individual sites. Differences in probing 
attachment levels may also reflect changes in the inflammatory status and 
resistance to probing at the base of the pocket rather than true connective 
tissue loss or gain following therapy (Lindhe et al., 1982). Moreover, limited 
reproducibility in probing measurements can adversely affect data. At an 
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individual site, bleeding on probing is a clinical indicator for active inflammation 
and is a reflection of decrease in collagen density and fragility of blood vessels 
(Polson et al., 1981, Greenstein et al., 1981). Although multiple studies report 
bleeding on probing as a relatively good predictor of future attachment loss 
(Badersten et al., 1990, Lang et al., 1986), others note the limitations of 
bleeding on probing as a predictor of future attachment loss (Haffajee et al., 
1983, Goodson, 1986). Further research has concluded that bleeding on probing 
has a weak correlation with future attachment loss and should be used as a 
‘criterion for stability rather than using as a predictor of disease activity’ (Cobb, 
2002, Lang et al., 1986). Mean reduction in bleeding on probing percentage 
reported in a recent review of the literature following non-surgical periodontal 
therapy was that of approximately 45% (Cobb, 2002). 
 
Periodontal probing depth has been identified as a particular strong indicator for 
determining further disease progression potential (Badersten et al., 1987, 
Zimmermann et al., 2015) and forms the basis of several historical and current 
classifications of periodontitis (Papapanou et al., 2018). A common finding in 
assessment of pocket depth reduction is that of grouping pockets into three 
categories for assessment: 1-3 mm, 4-6 mm and >6 mm. Each of these categories 
can be expected to respond to non-surgical therapy with an approximate 
reduction in probing depth of 0.4 mm ± 0.2 mm, 2.0 mm ± 0.4 mm, 2.6 mm ± 1.0 
mm (at 12 months) respectively (Heitz-Mayfield et al., 2002). The response to 
non-surgical therapy is lessened when multi-rooted teeth (Loos et al., 1989), 
including those with furcation involvement are treated by non-surgical 
(Badersten et al., 1987, Loos et al., 1989) or surgical means (Pihlstrom et al., 
1984). These findings illustrate the inherent difficulties in instrumenting the 
complex anatomy of multi-rooted teeth.  
 
Defining criteria for ‘success’ in relation to periodontal therapy can also prove 
challenging. Success can be defined at site level, or at whole patient ‘case’ 
level. The number of successfully treated sites is likely to be higher than the 
number of successfully treated cases (Lundgren et al., 2001). It has been 
suggested different success criteria should be applied to patients with differing 
levels of compliance, observed local disease resistance and value of the tooth 
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for the remaining dentition (Lundgren et al., 2001). Lindhe (Lindhe et al., 1982) 
developed a definition of ‘clinically successful non-surgical periodontal therapy’ 
as ‘resolution of gingivitis and reduction of sites with deep pockets (>4mm 
probing depth). This definition however is perhaps deliberately vague, as it is 
recognised that not all patients respond predictably to periodontal therapy. A 
2001 study (Lundgren et al., 2001) suggested an ‘evaluation criteria staircase’, 
in order of descending value of success –probing pocket depth ≤4 mm; no clinical 
signs of gingival inflammation; no bleeding on probing; no further loss of 
attachment and no further loss of alveolar bone. Successful treatment could 
then be categorised as levels on the staircase. A 2002 systematic review (Heitz-
Mayfield et al., 2002) on the topic of non-surgical periodontal treatment 
outcomes used ‘reduction in periodontal probing depth, maintenance or 
improvement in clinical attachment level and reduced bleeding on probing 
incidence’ as their criteria for a successful case. Further evidence based 
definitions of success are summarised by SDCEP (Scottish Dental Clinical 
Effectiveness Programme) in which optimal outcomes are plaque scores below 
15% (Axelsson et al., 2004, Carnevale et al., 2007), bleeding on probing scores 
below 10% (Axelsson et al., 2004, Carnevale et al., 2007, Tonetti et al., 1998) 
and probing depths of less than 4mm (Paulander et al., 2004). Ideally, all three 
of these targets would be met within the same patient. However, this is not 
always achievable. Thus, SDCEP have advised that patients showing 
improvements in oral hygiene, reduced bleeding on probing and a ‘considerable’ 
reduction in probing depths from baseline may be categorised as successful. It is 
therefore evident that defining success in periodontal therapy is not solely 
related to a single outcome measure – rather a combination of multiple - most 
commonly periodontal probing depth and bleeding on probing scores. Achieving 
all parameters of success is a rare event and adopting compromised levels of 
success has thus become necessary within the current models.  
 
1.7 Systemic Effects of Periodontal Treatment  
Non-surgical periodontal treatment consists of thorough supra gingival and 
subgingival debridement, using a combination of ultrasonic and hand 
instruments. Combined with patient compliance with bespoke oral hygiene 
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instruction, this treatment has consistently demonstrated significant 
improvements in multiple clinical parameters of success including reduced 
bleeding on probing, probing attachment levels and plaque scores (Badersten et 
al., 1981). The physical act of non-surgical instrumentation results in 
unavoidable perturbation to the periodontium. It is assumed that operator 
induced physical displacement of periodontal microorganisms into local tissues 
and gingival capillaries allows bacteria to reach the circulation. The incidence of 
bacteremia following periodontal therapy has been reported to be in the range 
of 13%-70% (Forner et al., 2006, Kinane et al., 2005, Lofthus et al., 1991). 
Incidence of bacteremia following ultrasonic scaling, periodontal probing and 
toothbrushing, was reported as 23%, 16% and 13% respectively (Kinane et al., 
2005). Moreover, the DNA of periodontal pathogens has been identified within 
surgically removed atherosclerotic plaques (Haraszthy et al., 2000, Okuda et al., 
2001). This paradigm of systemic spread of oral microorganisms following dental 
treatment is the basis of an ongoing discussion with regards to requirement for 
antibiotic prophylaxis during invasive dental treatment, including the non-
surgical treatment of periodontal disease. Currently, NICE (National Institute for 
Health and Care Excellence) guidelines dictate antibiotic prophylaxis is not 
recommended routinely for people undergoing dental procedures (Centre for 
Clinical Practice At, 2008). In contrast, the 2007 US (Wilson et al., 2007, Habib 
et al., 2015) and 2009/2015 European guidelines advise antibiotic prophylaxis 
regularly for patients with prosthetic heart valves, a positive history of infective 
endocarditis or congenital heart disease who are undergoing invasive dental 
procedures. 
 
Potential mechanisms for the systemic dissemination of periodontal bacteria and 
their products have been proposed. The first relates to the periodontal pocket 
being separated by only a few cells from the gingival micro-capillaries and it is 
thought bacteria may have potential to cross this layer and enter circulation via 
a transcellular mechanism (Takeuchi et al., 2011). Another relates to the ability 
of pathogens to survive within human immune cells, this remains theoretical 
however (Carrion et al., 2012, Zeituni et al., 2009). Perhaps the most likely 
mechanism is that of bacteria entering the blood stream after physical 
perturbation of the gingivae (Reyes et al., 2013) – through, for example, 
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mastication, toothbrushing or periodontal instrumentation. This systemic 
inoculation of bacteria and their by-products has been shown to result in 
systemic inflammation and bacteraemia. A 2005 study (Kinane et al., 2005) 
reported an incidence of bacteraemia of 20%, 13%, and 3% for periodontal 
probing, ultrasonic subgingival instrumentation and toothbrushing respectively. 
Forner et al (Forner et al., 2006) reported an incidence of 70% of bacteraemia 
following non-surgical periodontal treatment – however patient numbers were 
limited to 20 subjects. This potentially high incidence of bacteraemia may 
explain resulting systemic inflammation. 
 
It would therefore appear compelling that bacteria and their by-products are 
disseminated following non-surgical periodontal therapy. As is apparent, this 
varies according to intervention, individual patient variation, sampling methods 
and population studied. The long-term implications for other body systems, 
existing chronic diseases and of unknown effects of systemic bacterial 
dissemination are topics of developing contemporary research. To aid our 
understanding of the host response following bacteriaemia after periodontal 
treatment specifically, a variety of blood markers have been studied, which will 
now be discussed. 
 
There are several hallmark serum markers of systemic inflammation, with 
relevance to the effects of periodontal treatment. The most widely studied of 
these include C-reactive protein, interleukin 6 (IL-6), interleukin 1 (IL-1) and 
Tumour Necrosis Factor Alpha (TNF alpha). The latter three each being one of 
multiple cell signalling proteins known as cytokines. A 2004 study (Ide et al., 
2004) monitored TNF alpha and interleukin-6 levels within a non-smoker patient 
cohort with moderate/severe periodontal disease. Non-surgical periodontal 
treatment was provided over a 60-minute period, instrumenting all diseased 
sites within the mouth. Blood samples were taken at various time points 
following treatment and compared to baseline. Significant increases in both TNF 
alpha and IL-6 occurred following treatment. Unusually, no significant change in 
serum CRP was noted – this is in contrast with the consensus finding of an 
increase in CRP following periodontal therapy. The investigators also 
demonstrated full clearance of bacterial endotoxin from serum within 15 
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minutes of periodontal treatment. This is in keeping with a 2006 study by Forner 
et al. (Forner et al., 2006) who identified rapid elimination of bacterial 
endotoxin within 1 hour in the studied population. Again, Forner’s group found 
levels of IL-6 had significantly increased 8 hours following non-surgical 
treatment. Disease severity was also linked with levels of preoperative IL-6 by 
this study and others (Mengel et al., 2002, Buhlin et al., 2003). In relation to 
CRP levels following treatment, a recent 2018 study (Morozumi et al., 2018) 
identified a 5-fold increase in CRP at the 24-hour mark following non-surgical 
periodontal treatment. D’Aiuto’s study (D'aiuto et al., 2004a) of otherwise 
healthy subjects with severe chronic periodontitis reported a 10-fold increase in 
CRP following non-surgical treatment.  
 
The majority of recently conducted studies report a predictable increase in 
combinations of CRP, IL-6, and TNF alpha following non-surgical periodontal 
treatment (D'aiuto et al., 2004a, Graziani et al., 2015, Morozumi et al., 2018, 
Radafshar et al., 2010, D'aiuto et al., 2007, Tonetti et al., 2007, Kaptoge et al., 
2010). The increase and subsequent resolution in CRP and associated factors has 
been studied longer term following treatment. Two authors (Zhou et al., 2013, 
Marcaccini et al., 2009) identified CRP and IL-6 concentrations returning to 
around baseline levels 3 months after therapy. A 2010 study (Radafshar et al., 
2010) reported a significant decrease in serum CRP at 4 months, to a level below 
those at baseline. This study by Radafshar et al. investigated CRP and white 
blood cell counts prior to, and four months following, non-surgical root surface 
debridement and adjunctive chlorhexidine pocket lavage within a cohort of 
thirty-five otherwise healthy individuals. In relation to serum CRP reduction, 
1.85mg/L was achieved following a mean pre-treatment value of 2.32mg/L, 
representing a 20% reduction. These findings have identified potential longer-
term implications of non-surgical periodontal treatment upon the immune 
system. 
 
From a clinical perspective, the question arises whether quadrant scaling or full 
mouth debridement within a short period of time affects the inflammatory state 
of the patient. Mongardini (Mongardini et al., 1999) and Quirynen (Quirynen et 
al., 1999) investigated the effects of full versus partial mouth disinfection in a 
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mixed aggressive and severe chronic periodontitis patient cohort. 50% of 
patients who underwent full mouth disinfection reported pyrexia over the 
following 12 to 24 hours – indicating a possible significant disturbance of 
systemic inflammatory regulation. Increased body temperatures were also found 
in studies by Morozumi (Morozumi et al., 2018) in 2018 and Graziani in 2015 
(Graziani et al., 2015). Clinical outcomes showed no clinically relevant 
differences between one stage full mouth debridement – consisting of full mouth 
instrumentation within 24 hours – and the quadrant by quadrant approach. 
Graziani et al (Graziani et al., 2015) compared full mouth versus quadrant non-
surgical periodontal treatment on acute-phase inflammatory marker levels 
within a randomised controlled trial of ninety subjects. Full mouth treatment 
resulted in a greater acute phase response 24 hours after treatment. Compared 
to baseline, this consisted of a 3-fold increase in CRP levels, 2-fold increase in 
IL-6 levels with a slight increase in TNF alpha levels when compared to quadrant 
scaling. However, 3 months following treatment, both full mouth and quadrant 
scaling groups showed no significant difference in systemic inflammatory marker 
levels and did not identify a net reduction in inflammatory markers, compared 
to baseline. Despite the relatively small patient numbers within these studies, 
these findings have potential implications for our daily practice. 
 
Residual periodontal pocketing following non-surgical therapy has been shown to 
be associated with numerous factors including initial disease severity, higher 
preoperative bleeding indices and cigarette smoking (Tonetti et al., 1998). One 
possible treatment approach for residual pocketing is that of periodontal 
surgery. Graziani et al. (Graziani et al., 2010) investigated the effects 
periodontal surgery may have upon systemic inflammation. Subjects were 
treated with non-surgical periodontal therapy, followed 180 days later by two 
episodes of surgical intervention for residual sites with PPDs >5 mm. It was found 
the greatest increase in post-operative CRP was associated with non-surgical 
therapy. This result may perhaps be explained by the comparatively localised 
intervention of surgical therapy, compared to the generalised and potentially 
more invasive non-surgical treatment stage.  
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1.8 Systemic Disease and Periodontal Treatment 
A recent systematic review and meta-analysis (Teeuw et al., 2014) suggested 
patients with co-morbid diseases benefitted more from periodontal treatment, 
compared to healthy controls. In this instance, ‘benefitted’ refers to reduction 
in surrogate markers of cardiovascular disease – including serum reductions of 
CRP, IL-6, TNF alpha, total cholesterol and HDL-C. These diseases all share the 
commonality of chronic inflammation and often share common risk factors such 
as obesity and smoking habit. The first of these conditions is that of 
cardiovascular disease. Population studies have identified acute inflammation as 
a significant risk factor for vascular events such as myocardial infarction or 
stroke (Smeeth et al., 2004).  Patients with cardiovascular disease have a pre-
existing vascular dysfunctional state. Further disturbance due to periodontitis 
and its treatment has potentially significant clinical implications. Persistent low-
grade inflammation is thought to be relevant to vascular diseases and vascular 
risk (Wu et al., 2000); however, the specific mechanisms are currently not well 
understood (Kaptoge et al., 2010). The general population tend to have 
relatively stable levels of inflammatory markers, aside from small spikes related 
to low level infections or trauma (Pepys and Hirschfield, 2003). In healthy 
adults, the baseline concentration of CRP has been reported at values between 
<1mg/l and 10mg/L (Pepys and Hirschfield, 2003, Li et al., 2010, Patil and 
Desai, 2013). This value may increase by up to 10,000 fold during periods of 
acute infection or significant trauma (Pepys and Hirschfield, 2003) – for 
example, acute periapical abscess and road traffic accident respectively. 
Chronic periodontitis has been shown to result in a raised baseline level of CRP – 
within the region of 2-7mg/l (Goyal et al., 2014, Slade et al., 2003, Thakare and 
Thakare Ks, 2010). This range is explained by variations in environmental factors 
within studied populations. The CANTOS study (Ridker et al., 2017) of 2017 
studied 10,061 patients with previous myocardial infarction and a CRP level of at 
least 2mg. Patients received drug interventions targeting an inflammatory 
mediator pathway. Clinically relevant hard outcomes of nonfatal myocardial 
infarction, nonfatal stroke or cardiovascular death were measured. The authors 
assumed each drug intervention would result in a 20% lower rate of event 
outcome than placebo. With this assumption, in order to gain a 90% power, 1400 
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primary end points were required from the 10,061 study participants. The most 
effective dose demonstrated a 70% reduction in CRP levels. effects. Baseline 
median CRP level across all subjects was 4.15 mg/L which reduced to 1.80mg/L 
following drug intervention at the three-month mark. This reduction was largely 
maintained throughout the study’s 48-month duration, if all drug dose effects 
are combined. The authors concluded reduction in even low-grade inflammation 
has beneficial effects on hard clinical outcomes of cardiovascular disease. As in 
otherwise healthy periodontitis patient populations, studies in patients with CVD 
have shown a modest improvement in acute phase inflammatory markers as a 
result of periodontal treatment (Koppolu et al., 2013) with associated short 
term spike in inflammatory markers in patients with cardiovascular disease. An 
observational study by Ridker et al. (Ridker et al., 2000), studying 14,916 
healthy men and controlling for risk factors relevant to cardiovascular disease, 
observed increased levels of IL-6 at baseline resulted in greater risk of 
developing myocardial infarction later in life. A level of 1.81 pg/ml of 
circulating serum IL-6 vs a level of 1.46 pg/ml was shown to result in a 
significant increase in myocardial infarction incidence in this study. To put this 
figure into perspective, serum IL-6 has been demonstrated to reside around 5-16 
pg/ml for patients suffering from generalised chronic periodontitis (Blach et al., 
2009, Monea et al., 2014, Sezer et al., 2012). A 2013 joint statement from the 
European Federation of Periodontology and the American Academy of 
Periodontology (Tonetti and Van Dyke, 2013) concluded consistent and strong 
epidemiologic evidence exists that periodontitis imparts increased risk for future 
cardiovascular disease development. In partial agreement, the American Heart 
Foundation released a scientific statement in April 2012 stating observational 
studies to date support an association between periodontitis and cardiovascular 
disease. However, ‘they do not support a causative relationship’. Further well-
structured interventional trials are required to establish a direct cause-effect 
relationship, in particular in relation to the beneficial effects of treatment.  
 
Recent interventional studies have analysed endothelial function following 
periodontal therapy, as a method of predicting possible risk of vascular events. 
The endothelium is the cellular lining of blood and lymphatic vessels. Healthy 
endothelium is responsible for regulating vascular resistance and the release of 
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various mediators involved in regulation of oxidative stress – thus maintaining a 
healthy cardiovascular system. Tonetti et al (Tonetti et al., 2007) assessed 
endothelial function by means of the diameter of branchial artery flow, 
comparing full mouth and quadrant debridement protocols. Twenty-four hours 
after periodontal therapy, levels of CRP and IL-6 were significantly increased. 
Full mouth periodontal treatment was identified as causing acute, short term 
systemic inflammation and endothelial dysfunction. However, 6 months 
following therapy, endothelial function was improved beyond baseline levels – 
resulting in a cardiovascular benefit to the patient.  
 
Improvements in endothelial function following periodontal treatment were 
consistently reported in a 2014 systematic review and meta-analysis by Teeuw 
(Teeuw et al., 2014). Benefits upon CRP, TNF alpha, fibrinogen, total 
cholesterol and HDL-C were identified. Humphrey (Humphrey et al., 2008) 
reported an increase in relative risk for developing cardiovascular disease in 
subjects with untreated periodontitis in the range of 1.24 to 1.34. With regards 
to the risk of suffering a stroke, another meta-analysis in 2003 (Janket et al., 
2003) reported a relative risk of 1.85 compared to subjects without periodontal 
disease. Teeuw’s systematic review reported endothelial and cardiovascular 
benefits from periodontal therapy are sustained over at least 6 months with the 
overall effect on endothelial function from periodontal disease being positive.  
 
A review on the subject of the impact of periodontal treatment on systemic 
health by D’Aiuto (D'aiuto et al., 2013) warned that the proliferation of a 
surrogate outcome such as endothelial dysfunction as a predictor of future 
cardiovascular risk and outcomes should be used with caution. The authors 
describe it as a ‘research measure that is greatly confounded by multiple 
methodological and environmental factors’ and as such may prove unreliable. 
They suggest ‘alternative, more proven measures of sub-clinical atherosclerosis 
such as c-IMT may show a more consistent association with future risk of 
cardiovascular disease’. The absolute marker of cardiovascular outcome would 
be a cardiovascular event such as a myocardial infarction however this has 
evident ethical implications for study design. The American Heart Association in 
2012 (Lockhart et al., 2012) issued a statement concluding that no causative 
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relationship between periodontal disease and atherosclerotic vascular disease 
currently exists. As is evidenced in the literature, periodontal intervention has 
potential to result in overall reduction in systemic inflammation and 
improvement in endothelial function in short term studies, however, evidence of 
prevention of cardiovascular events is notably lacking.   
 
Poor diabetic control may lead to diabetic complications such as neuropathy, 
retinopathy, ketoacidosis and high blood pressure among others. A 2013 review 
(Engebretson and Kocher, 2013) established consistent albeit modest effects 
upon HbA1c levels as a result of periodontal therapy in subjects with Type 2 
diabetes. Some individual studies record significant improvements in HbA1c 
levels following periodontal therapy. A Cochrane Collaboration review (Simpson 
et al., 2015) found a mean percentage reduction in HbA1c of 0.29% 4 months 
after treatment. The review concluded that insufficient evidence was available 
to comment after a four-month period, with no single periodontal treatment 
modality emerging as more beneficial to diabetic control. More recently, 
D’Aiuto’s review in 2017 (D'aiuto et al., 2017) concluded there is no evidence 
that the beneficial effect of periodontal treatment upon diabetic control is 
sustained over the long-term nor reduces the prevalence of long term diabetic 
complications. To evidence available to date, suggests periodontal treatment 
has favourable effects upon HbA1c and by extension diabetic control. However, 
more well designed, long term interventional trials are required to substantiate 
this. 
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1.9 Summary  
Periodontitis is evidently a multifaceted, complex disease process with 
emergent links to systemic health and disease. Non-surgical treatment for 
periodontitis is effective by various instrumentation approaches and has a 
wealth of supporting evidence, as presented in this chapter. Instrumentation 
approach, thus far, has been largely down to clinician preference. The economic 
burden of periodontal disease is only increasing, and time and cost efficiency of 
treatment may prove to be an important factor for future service development 
in the United Kingdom – this warrants exploration. Further detailing of the 
clinical effectiveness and the patient centred nature of periodontal 
instrumentation techniques would be highly valuable. The comparative effects 
of instrumentation techniques upon markers of systemic inflammation is another 
topic of significant interest to develop the contemporary evidence base in 
modern, holistic periodontal treatments. Studies carried out within the field of 
systemic inflammation following periodontal therapy have, thus far, been done 
solely on the basis of a combination approach to treatment. A need therefore 
exists for comparative research investigating inflammatory outcomes of non-
surgical instrumentation techniques for the treatment of periodontitis. 
 
This study aims to explore clinical and systemic inflammatory outcomes in 
relation to three methods of non-surgical instrumentation for the treatment of 
periodontitis – ultrasonic instrumentation, hand instrumentation and a 
combination approach (‘treatment as normal’). Multiple research questions were 
developed – each aimed at addressing a specific facet of interest. 
 
 
1.10 Objectives and Research Questions 
The objective of the current work is to compare three techniques of non-surgical 
treatment for the treatment periodontal disease – exclusively ultrasonic 
instrumentation, exclusively hand instrumentation and a combination approach. 
This study is a post-hoc analysis of two existing studies. This analysis was 
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designed to evaluate periodontal treatment (comparing baseline and ninety days 
following completion of treatment), using three different instrumentation 
methods with regards to clinical outcome (measured via PISA, PPD, % Pockets 
≥5mm, BOP and plaque scores), objective ‘success’ of treatment (measured 
against published criteria), time taken for treatment (measured in minutes), 
systemic inflammatory outcomes (measured via CRP level), financial aspects and 
patient reported outcomes. The research questions were as follows: 
1. Clinical parameters of periodontal disease status 
a. What are the effects on clinical periodontal outcomes, measured 90 
days following treatment (comparing baseline with day 90), for each 
treatment group? 
b. Is there a difference in clinical outcome between treatment groups? 
c. How is clinical outcome affected by particular key confounders? 
d. Was treatment for study patients successful in the context of 
published criteria of a successful outcome of periodontal treatment? 
2. Time taken for treatment 
a. Is there a difference in time taken for treatment comparing 
treatment with hand instruments, to ultrasonic instruments, to 
combination instruments? 
3. Systemic inflammation 
a. Does CRP immediately increase following periodontal treatment? 
b. Is there a difference between treatment groups with respect to day 
90 post-treatment levels of CRP? 
4. Financial Implications  
a. What are the costs of providing periodontal treatment within a 
secondary care UK dental hospital setting - comparing single modality 
treatment provided using a full mouth debridement approach 
(assuming 2 visits in 24 hours) to combination treatment provided 
using a quadrant by quadrant approach? 
5. Patient reported outcomes 
a. What were patient experiences of receiving periodontal treatment?  
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The work presented in this thesis combines data sets from two separate studies. 
Both studies were carried out within Glasgow Dental Hospital. One study, ‘Study 
1,’ was a randomised controlled trial comparing use of hand with ultrasonic 
instruments on changes in systemic inflammation following non-surgical 
periodontal treatment. The other, ‘Study 2,’ was a cohort study in which 
patients were treated with a ‘standard of care’ approach that used both hand 
and ultrasonic instruments and also investigated systemic inflammation following 
periodontal treatment. The research questions addressed in this work sought to 
compare different aspects of periodontal treatment provided across a total of 
three treatment groups. Each of the two studies is described individually below, 
and the approach to comparing the three treatment groups described 
subsequently.  
 
2.1 Randomised Controlled Trial (RCT) – ‘Study 1’  
This Randomised Controlled Trial, “The Immune Response After Periodontal 
Treatment” (IRAPT) was designed to evaluate a primary outcome of systemic 
inflammatory changes following either hand instrumentation or ultrasonic 
instrumentation for the non-surgical treatment of periodontal disease. This trial 
was registered through ClinicalTrials.gov, ID – NCT03501316, prior to 
recruitment. The Research Ethics Committee reference was 18/NI/0059 and 
ethics was approved on 13th March 2018 by the Office for Research Ethics 
Committees Northern Ireland (ORECNI). The study was active between February 
2018 and June 2019. 
 
The PICO question that IRAPT aimed to answer: ‘For patients with periodontitis 
(problem/population), following non-surgical periodontal treatment 
(intervention), is there a difference in changes in systemic inflammatory 
markers (outcome) comparing treatment provided by exclusively hand 
instruments or exclusively ultrasonic instruments (comparison)?’ 
 
‘IRAPT’ was a single centre randomised controlled trial with two intervention 
arms, with patients returning at day 1, day 7 and day 90 post treatment, 
following separate baseline and treatment visits. Patients were referred by their 
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General Dental Practitioner (GDP) to Unit of Periodontics at Glasgow Dental 
Hospital for specialist management of periodontal disease. Patients were 
approached during new patient assessment clinics in the Unit of Periodontics. All 
participants gave informed, written consent.  
 
 
2.1.1 RCT - Inclusion and Exclusion Criteria 
The inclusion criteria for the RCT were:  
• Male or female patients aged 18 years to 70 years inclusive 
• Probing depths ≥ 5 mm on 2 or more teeth at non-adjacent sites with 
cumulative probing depths of ≥ 40 mm. Cumulative probing depth was 
calculated by examining six sites on each tooth. The deepest site on each 
tooth was recorded and if the value was greater than 4 mm, this 
contributed to the cumulative total, with each tooth being only counted 
once towards the total to ensure extent of disease. The use of cumulative 
probing pocket depth ensured a minimum level of periodontal disease (≥ 2 
sites with probing depths with ≥ 5 mm) (Page and Eke, 2007, Tonetti and 
Claffey, 2005), and has recently been adopted as a means of including 
patients with a disease burden that is potentially relevant to systemic 
inflammation (Serban et al., 2019, Lopez-Oliva Santa Cruz, 2018).  
 
Exclusion criteria included:  
• known or suspected high risk for tuberculosis,  
• hepatitis B or HIV infections;  
• required interpreter/non-English language written material to understand 
and provide written, informed consent, or any other reason for being 
unable to provide written, informed consent;  
• history of bleeding diathesis;  
• pregnant or lactating females;  
• self-reported diagnosis of any systemic illnesses including cardiovascular, 
renal, and liver diseases, and/or regular use of medication to control 
systemic illness; 
 
 
 
45 
• any pharmacological treatment within 1 month before the beginning of 
the study, including routine use of any over the counter medications, 
• specialist periodontal treatment in the previous 6 months. 
 
 
2.1.2  RCT - Study Procedures  
Following referral to Glasgow Dental Hospital by their GDP, eligible patients 
were initially informed of the existence of the study and approached by the 
consultant or his/her representative who was treating the patient (specialty 
dentist, dental core trainee, hygienist or specialty trainee in Restorative 
Dentistry). This initial contact was to provide the patient with the Participant 
Information Leaflet (PIL – Appendix I) and establish whether they would consider 
taking part. At the subsequent visit (Screening visit), the researcher asked 
whether the patient would like to take part and obtained written consent 
(Appendix II). At each stage, it was made clear to the patient that participation 
is voluntary and they could leave the study at any time without their care being 
affected. 
 
At the baseline visit, patients were provided with detailed oral hygiene 
instruction, dental health education and a full-mouth supragingival scale (using a 
Cavitron Powerline FSI-10 30K FITGRIP Insert), irrespective of treatment group. 
Medical history was confirmed to be clear and smoking status was recorded as 
‘current, former or never’, with detail on amount smoked and time period as 
appropriate. All interventions and clinical data collection were carried out by an 
experienced dental hygienist (DM) and/or specialist trainee in restorative 
dentistry (MP). SC was the named principle investigator. For calibration, both 
examiners completed pocket charts on the first twelve patients entering the 
study. Charts were assessed for agreement and a kappa score was calculated 
(0.66). Following collection of blood samples at day 1 post treatment, all 
patients were provided with an electric toothbrush (Oral-B Pro 2000) to 
standardise self-performed plaque control prior to day 90 follow-up. 
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2.1.3 RCT - Clinical Outcomes  
At baseline and day 90, clinical parameters (full-mouth plaque, bleeding scores 
and detailed 6-point periodontal pocket charting) were assessed using a PCP-12 
periodontal probe at six sites per tooth, excluding third molars (unless other 
molar units missing), with measurements rounded to the nearest millimetre. 
Following collection of clinical data, the Periodontal Inflamed Surface Area 
(PISA) was calculated (Nesse et al., 2008).  
 
Regarding systemic inflammation data: CRP was measured at all timepoints 
(baseline, day 1, day 7 and day 90). Levels of serum CRP were determined by 
high sensitivity immunoturbidometry using the Cobas C311 analyser (Cobas, 
Roche Diagnostic, Mannheim, Germany). CRP was detected in all samples. All 
laboratory assays were conducted following study completion by laboratory staff 
masked to treatment groups. Analysis of serum CRP was performed at the British 
Heart Foundation Glasgow Cardiovascular Research Centre. Intra- and inter-
assay coefficients of variations were <5%. A single patient in the Hand 
Instrumentation group was excluded from analysis following completion of 
interventions due to an abnormally high baseline CRP level and thus was deemed 
as not adhering to inclusion/exclusion criteria. 
 
2.1.4 RCT - Randomisation  
Patients were randomised to one of two treatments (HI or UI) (Figure 2-1, Figure 
2-2). Randomization was performed using a computerised random number 
generator (using permuted blocks of 4 and 6) by the study statistician. Patients 
were stratified according to smoking status prior to randomization. Concealment 
of allocation was achieved using an opaque sequentially numbered envelope 
containing the allocated intervention arm for the patient. This was opened 
immediately before treatment was commenced. 
 
Patients and clinicians were unaware of intervention until the intervention visit. 
Clinicians were blinded to treatment groups during post-treatment follow up 
visits (day 1, day 7, day 90). Statistical and laboratory personnel remained 
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blinded to specific patient group allocation throughout the entire process via 
patient codes. The key linking codes to patients was available only to the chief 
investigator - and was kept on a separate system. Intervention codes were only 
available once all analyses took place. 
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Figure 2-1: Instruments used in each Randomised Controlled Trial Treatment 
Group 
Periodontal instruments used within the two treatment groups of the randomised 
controlled trial: exclusively ultrasonic instruments (upper panel) or exclusively hand 
instruments (lower panel). 
Hand Instruments (left to right)-  
Gracey 1/2,  
Gracey 7/8,  
Gracey 11/12,  
Gracey 13/14,  
Columbia 4L-4R  
Hoe Scaler-lateral,  
Hoe Scaler-posterior; LM Dental 
Ultrasonic Instruments (left to right)-  
Cavitron® Slimline® 10S 30K, 
Cavitron® Slimline® 1000 30K,   
Cavitron® Slimline® 10L 30K,  
Cavitron® Slimline® 10R 30K,  
Cavitron® Thinsert® 30K,  
Cavitron® Powerline® 1000 30K; Dentsply Sirona 
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Figure 2-2: CONSORT flow diagram for randomised controlled trial.  
Blood samples were not obtained from one patient at day 1 (UI group), one patient at 
day 7 (HI group) and one patient at day 90 (UI group). Therefore, for analysis of serum 
inflammatory markers; at day 1 (UI; n=17, HI; n=19), day 7 (UI; n=18, HI; n=18) and day 
90 (UI; n=17, HI; n=19). For analysis of clinical parameters and treatment time (UI; 
n=18, HI; n=19).   
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Full-mouth debridement was carried out within a 24-hour period. All but one 
patient completed treatment within the same day; a single patient completed 
debridement on consecutive days, within 24 hours, due to patient availability. 
Debridement was completed using Gracey and Universal curettes (Gracey 1/2, 
Gracey 7/8, Gracey 9/10, Gracey 11/12, Gracey 13/14, Columbia 4L-4R) and 
hoes (Hoe Scaler-lateral, Hoe Scaler-posterior, LM Dental) for the hand 
instrumentation (HI) group; or Cavitron Ultrasonic inserts (Cavitron® Thinsert® 
30K, Cavitron® Slimline® 10S 30K, Cavitron® Slimline® 10L 30K, Cavitron® 
Slimline® 10R 30K, Cavitron® Slimline® 1000 30K, Cavitron® Powerline® 1000 
30K; Dentsply Sirona) for the ultrasonic instrumentation (UI) group (Figure 2-1).  
 
Treatment was provided with the aid of local anaesthetic and timed by digital 
stopwatch from the point of first contact between instrument and tooth surface. 
Debridement was carried out until no supra or subgingival plaque or calculus 
deposits were detectable by visual examination with magnification or by tactile 
examination. Patients were recalled following periodontal treatment at day 1, 
day 7, and day 90. Samples were collected as per baseline visit (serum, whole 
blood, saliva, subgingival plaque, GCF) at each timepoint, with clinical 
parameters measured at day 90 only. Following day 90 review, any further 
treatment need was evaluated by a Specialist in Periodontology. 
 
2.1.5  RCT - Sample size calculation 
The primary outcome for the randomised controlled trial was: 
 - Serum CRP levels at day 1 post-treatment 
Secondary outcomes were: 
- CRP at day 7 and day 90 
- Other systemic inflammatory markers (IL-6, TNF alpha) at day 1, day 7 
and day 90 
- Subgingival plaque microbiome analysis at day 1, day 7 and day 90 
- Clinical parameters at day 90 (PISA, PPD, % Pockets ≥5mm, BOP, CAL) 
- Treatment time 
- Patient reported outcomes 
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The sample size calculation was based on data from a previous study that 
measured changes in CRP following periodontal treatment (Graziani et al., 
2015).  From this study, a difference of 3.5 mg/l (SD=3 mg/L) in serum CRP was 
detected between the two groups receiving different schedules of periodontal 
treatment (quadrant vs full-mouth debridement), 24 hours after completion of 
treatment. This magnitude of difference has been deemed clinically relevant in 
recent guidelines (Sanz et al., 2020), therefore this was considered a reasonable 
estimate of the minimum clinically relevant difference. At 80% power and a 5% 
significance level, a sample size of n=34 (17 in each group) was required to 
detect a minimum difference of at least 3mg/l (=1 SD) between CRP levels at 
primary endpoint (day 1) between the two groups (HI vs UI). To account for 
potential drop-out of 20%, 42 eligible patients were recruited.   
 
2.1.6 RCT – Summary of Data Yield 
This trial provided clinical data relating to outcomes of treatment with 
exclusively hand instruments or exclusively ultrasonic instrumentation, using a 
full mouth approach within 24 hours. All patients included for final analysis in 
this trial (Figure 2-2) were included in the current post hoc analysis study.  
 
 
2.2 Cohort Study - ‘Study 2’  
The comparator data set (combination instrumentation) was gathered from a 
cohort study (‘Immune Response in Periodontal Disease’) carried out within the 
same centre as the RCT. The study was active between August 2017 and 
September 2018.  The cohort study was designed as an exploratory study to 
evaluate changes in serum antibodies and other inflammatory mediators 
following periodontal treatment. Treatment in this study was delivered using a 
combination of hand and ultrasonic instrumentation using a quadrant approach 
by a single experienced dental hygienist (DM). Data analysis for the purposes of 
the current study was carried out by MP. SC was the named principle 
investigator. A further extension of this study involved retention of surplus tissue 
during surgical periodontal treatment – this aspect is not discussed herein as it is 
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not relevant to the current study. The research ethics committee number (REC 
reference) for this study was 14/LO/2064. The Integrated Research Application 
System ID was 149159. 
 
2.2.1 Cohort Study – Inclusion and Exclusion Criteria 
Inclusion criteria were as follows: 
• Written informed consent 
• Male or female ≥18 years of age 
• Periodontal treatment required at Glasgow Dental Hospital 
 
Exclusion criteria were: 
• Known or suspected high risk for tuberculosis, hepatitis B or HIV infections  
• Require interpreter/non English language written material to understand 
and provide, or any other reason for being unable to provide written, 
informed consent 
• History of bleeding diathesis 
 
 
2.2.2 Cohort Study – Study Procedures and Sample Collection 
 
2.2.2.1 Visit 1: New Patient Assessment  
Patients were referred then appointed on a new patient consultant clinic 
at which a clinical history and clinical examination were completed by a 
consultant or his/her staff. A treatment plan was then agreed with the 
patient. If this treatment plan included periodontal treatment at Glasgow 
Dental Hospital then the patient was provided with written (Patient 
Information Leaflet – Appendix III) and verbal information about the 
study. If the patient indicated they would consider participation in the 
study, they were appointed jointly to the Clinical Research Facility and 
the study hygienist (visit 2) following recorded informed consent 
(Appendix IV).  
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2.2.2.2 Visit 2: Initial treatment visit 
This visit was for initial periodontal treatment and collection of baseline 
clinical information including smoking status (‘current’, ‘former’, ‘never’) 
Periodontal Probing depths (PPD), Bleeding on Probing % (BOP) and plaque 
%. This visit included detailed oral hygiene instruction and a superficial 
ultrasonic scaling of the teeth (Cavitron® Powerline® 1000 30K; Dentsply 
Sirona). Consent for sample collection was confirmed and samples were 
collected by the research nurse (whole blood) and study hygienist (in the 
case of subgingival plaque, saliva and gingival crevicular fluid).  
 
2.2.2.3 Subsequent treatment visits 
The number of visits varied, subject to extent of treatment required and 
patient preference for treatment scheduling. At the final treatment visit, 
the study hygienist verbally enquired whether the patient was happy to 
continue participation in the study. If yes - then the review visit (at Day 
90 following treatment) was scheduled within the Clinical Research 
Facility for sample collection.  
 
2.2.2.4 Day 90 review visit:  
Patients were appointed to the Clinical Research Facility for review, 90 
days (±14 days) following completion of periodontal treatment, to assess 
requirement for further treatment with a consultant or training grade 
staff under consultant supervision. Data and samples were collected, as 
per visit 2 – periodontal probing depths, plaque %, BOP % and whole blood 
with the addition of plaque, saliva and gingival crevicular fluid. 
Techniques of clinical sample collection are identical to those described 
in Section 2.1.3. 
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Figure 2-3: Patient flow diagram for cohort study.  
Patients attended for periodontal treatment using a combination approach and 
provided over as many appointments as necessary – as judged by the treating research 
hygienist. 
  
(out with study) 
(out with study) 
(Day 90 post treatment) 
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2.2.2.5  Cohort Study – Summary of Data Yield 
This study provided clinical and systemic inflammation data pertaining to 
periodontal instrumentation using a combination of hand instruments and 
ultrasonic instruments.  
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2.3  Current Study Protocols 
2.3.1 Sample Size 
The sample size of the current study was dictated initially by the number of 
patients completing all interventions in each of the RCT’s two treatment groups 
(n=19; n=18 respectively) – “Study 1”. This information was used to select a 
similar number of patients (n=18) from the cohort study (“Study 2”) to serve as a 
third comparator group. The process of patient selection is described 
subsequently. This sample size was deemed sufficient to allow the assessment of 
trends for exploratory analysis.  
2.3.2  Patient Selection Process 
All patients in the RCT were included for analysis. Patients were selected from 
the cohort study by matching of patients to the inclusion/exclusion criteria as 
per the RCT to minimise heterogeneity in characteristics of patients. Therefore, 
all patients analysed in this study fulfilled the following inclusion/exclusion 
criteria: 
 
2.3.2.1 Inclusion criteria 
• Written informed consent 
• Male or female 18 years to 70 years inclusive 
• Periodontal treatment required at Glasgow Dental Hospital  
• Probing pocket depths >5mm on 2 or more teeth at non-adjacent sites 
with cumulative probing pocket depths of greater than or equal to 40 mm 
(Cumulative probing depth is calculated by evaluating all sites on each 
tooth. The deepest site on each tooth is recorded and if this value is 
greater than 4 mm this is ‘counted’ and the sum of all the teeth assessed 
in this way calculated.)    
 
2.3.2.2 Exclusion criteria 
• Known or suspected high risk for tuberculosis, hepatitis B or HIV infections  
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• Require interpreter/non English language written material to understand 
and provide, or any other reason for being unable to provide written, 
informed consent 
• History of bleeding diathesis 
•   Pregnant or lactacting females. 
•   Reported diagnosis of any systemic illnesses including cardiovascular, 
renal, and liver diseases, and/or regular use of medication to control 
systemic illness.  
•   Any pharmacological treatment within 1 month before the beginning of 
the study, including routine use of any over the counter medications.  
•   Specialist Periodontal treatment in the previous 6 months. 
2.3.3  Study Outcome Data 
 
2.3.3.1 Clinical Outcome Data 
Data on periodontal clinical outcomes were collected within the RCT and cohort 
studies. Periodontal outcomes were assessed via PISA, PPD, % Pockets ≥5mm, BOP 
and plaque scores. Systemic inflammatory outcomes were assessed via serum 
CRP level. 
 
Details of clinical outcome data collection techniques are presented in Section 
2.1.3 and a schedule of collection is presented in Figure 2-4. 
 
2.3.3.2 Financial Outcome Data  
Financial costs of periodontal treatment were estimated through discussion with 
onsite centralised medical device sterilisation services and NHS procurement 
staff. Salary data of individuals involved in periodontal care (clinicians, nursing 
and CCSD staff) was not included in the current data set as the aim was not to 
estimate the total treatment cost. The data focused on differences in ‘fixed’ 
costs (i.e. instruments) and time taken. The impact of salary costs varies 
according to staff type. Understanding time taken provides the multiplier for the 
appropriate staff cost.   
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Data were derived from protocols within the current studies thus all available 
inserts (Cavitron® Thinsert® 30K, Cavitron® Slimline® 10S 30K, Cavitron® 
Slimline® 10L 30K, Cavitron® Slimline® 10R 30K, Cavitron® Slimline® 1000 30K, 
Cavitron® Powerline® 1000 30K; Dentsply Sirona) for ultrasonic instrumentation 
and the full hand instrument scaling kit (Gracey and Universal curettes (Gracey 
1/2, Gracey 7/8, Gracey 9/10, Gracey 11/12, Gracey 13/14, Columbia 4L-4R) 
and hoes (Hoe Scaler-lateral, Hoe Scaler-posterior, LM Dental)) were considered. 
 
2.3.3.3 Patient Reported Outcomes 
Patients taking part in the RCT were presented with two open written questions 
at each follow up (Day 1, Day 7, Day 90). Questions were designed following 
collaboration with a behavioural psychologist and constructed to be open ended 
and minimise time commitment from trial patients. It was felt patients should 
not be burdened with an extensive questionnaire – in the context of other time 
commitments arising from the trial (e.g. blood sampling and follow up visits). 
These were as follows:  
 
• ‘Thinking about the treatment in your own words, can you describe 
the experience of treatment?’ 
And  
• ‘Is there anything that would have made it a better experience?’ 
 
These questions were posed to patients at Day 1, Day 7 and Day 90 after 
treatment and were selected to allow patients freedom to provide descriptions 
relating to treatment received. Following completion of questions, answers were 
collated, and themes analysed. 
2.3.4 Ethical Approval  
Ethical approval was granted by application to the Greater Glasgow and Clyde 
Health Board and Office for Research Ethics Committees Northern Ireland 
(ORECNI) for both studies which served to provide data for the current analysis.  
This study, being a post hoc analysis, required no separate ethical approval. 
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2.3.5 Patient Flow 
The patient flow through the RCT and cohort studies and data collection points 
are shown in Figure 2-4. The two studies are described in detail in Section 2.1 
and Section 2.2 of this chapter. 
  
 
 
 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-4 – Patient flow through respective studies.  
Please note trials did not occur in parallel. Patients were recruited from new patient periodontology clinics within 
Glasgow Dental Hospital. Following eligibility assessment and consent processes, patients within the randomised 
controlled trial underwent randomisation. A baseline visit was carried out which was consistent across both studies. 
Baseline clinical and systemic inflammation data collection occurred at this stage. Interventions were then provided as 
per separate study. Patients were reviewed 90 days following intervention completion, consistent across both studies, 
with post treatment clinical periodontal parameters and systemic inflammation data collection. 
Yes 
Diagnosed periodontitis and periodontal treatment planned at 
Glasgow Dental Hospital? 
Yes 
No 
COHORT STUDY 
Screening Visit 
Patient attends new patient clinic for examination and diagnosis. 
Assessed with respect to inclusion/exclusion criteria. 
Discharged for continuing care 
Baseline Visit 
Consent to participate? No 
Full periodontal charting, PGI, supragingival instrumentation, standardised oral hygiene instruction 
Screening Visit 
Patient attends new patient clinic for examination and diagnosis. 
Assessed with respect to inclusion/exclusion criteria. 
 
Hand 
Instrumentation 
(n=19) 
Diagnosed periodontitis and periodontal treatment planned at 
Glasgow Dental Hospital? 
Yes 
No No 
Study Information given 
Baseline Visit 
Consent to participate? 
Study Information given 
Continue patient journey  
(treatment at Glasgow Dental 
Hospital) 
Yes 
Randomisation  
(by computer generation)  
Data Collected:  
Baseline Clinical Periodontal Disease Parameters – PPD, BOP, Plaque % 
Baseline Inflammatory markers - CRP 
Ultrasonic 
Instrumentation 
(n=18)  
Combination 
Instrumentation   
(n=18) 
Treatment Visit 
Instrumentation of full mouth within 24 hours 
Treatment duration timed 
 
Treatment Visits 
 
Quadrant instrumentation over 
multiple visits   
 
 
Data Collected:  
Time required for treatment 
 
Review Visit (Day90 post treatment) 
Full Periodontal charting, PGI  
Re-evaluation for further treatment out-with study 
Data Collected:  
Post Treatment Clinical Periodontal Disease Parameters – PPD, BOP, Plaque % 
Day 90 Inflammatory markers - CRP 
 
RANDOMISED CONTROLLED TRIAL 
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2.3.6 Statistical Analysis  
All data were analysed using SPSS Software Version 25 (SPSS Inc. Chicago, IL, 
USA). All data were cleaned and checked for range errors/logical errors/ 
inconsistencies. 
 
Regarding Data Management, a file naming convention was adopted using 
unique, anonymised subject identifiers relevant to the data set. Data were 
transcribed from a paper form in the CRF (Clinical Research Facility) to a secure 
password protected directory on the university “One Drive” by MP and WJ. All 
personal identifiers were removed and replaced with an anonymised code. The 
link between the personal identifiers and anonymised code was held on a 
separate system and only accessible by SC (the PI). All files were categorised 
using intuitive filenames that denoted the date created, researcher inputting 
data and a relevant descriptor. Each file had an included ReadMe file which 
informed the user of what the naming convention is, when the data was created, 
how the data was created and what software is needed to open and interpret 
the data.  
 
Raw and analysed data were kept separate and identifiable through folder 
labels. Raw data was not edited. 
 
Data was stored through the University of Glasgow approved OneDrive for 
Business, only accessible to the researcher (MP). 
 
Access to data linking patient name to study code was restricted only to the 
chief investigator of the RCT and cohort studies (Professor Shauna Culshaw). 
 
Variables were described and summarised using means (standard deviations) or 
medians (Q1, Q3) as appropriate. 
 
All patients that completed interventions in the RCT were included in the 
current study apart from a single patient in the hand instrumentation group who 
was excluded as an outlier due to high baseline CRP.  
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Data were examined for normal distribution visually using histograms. Non-
parametrically distributed data were transformed by natural logarithmic 
transformation where appropriate.  
 
Baseline data were largely normally distributed (BMI, number of teeth, PPD, Full 
mouth BOP, Full mouth Plaque, CAL, Pockets ≥5mm); however, multiple 
variables showed non-normal distribution at Day 90 follow up (Pockets ≥5mm, 
BOP, Plaque). Univariate general linear models were used to test “between 
group” differences in clinical variables adjusting for baseline clinical outcome 
and key confounders (smoking status, treatment time, age, gender, number of 
teeth) where appropriate. Non-symmetric outcome (dependent) variables were 
Ln-transformed. Intra group comparisons were carried out using Wilcoxon signed 
rank test due to Day 90 data commonly being non-normally distributed. 
Parameter estimates (unadjusted and adjusted), 95% confidence intervals and 
exact p-values were all presented. 
 
Independent sample t-tests were used to test differences in treatment time 
between groups. Pearson’s correlation coefficients were used to examine the 
association between treatment time and disease severity (measured by PISA and 
% of pockets ≥5mm).  
 
Patient reported outcome qualitative data were analysed by descriptive analysis 
only, with the support of a behavioural psychologist, and emergent themes were 
identified and described.  
 
2.3.7  Modelling Strategy 
General Linear Models were used to assess the effect of different “treatment” 
groups on clinical outcomes. In the first instance univariable models were 
produced (Model 1), then models adjusting for the baseline clinical measure 
were produced (Model 2). Model 3 considered baseline measures for the clinical 
outcome and smoking status, Model 4 adjusted for baseline measures of clinical 
outcome, smoking status and treatment time and a final model, Model 5 was 
adjusted for baseline measures of clinical outcome, smoking status, treatment 
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time, age, gender and number of teeth. Changes in parameter estimates were 
used to quantify effects of confounders on clinical outcomes observed.  
 
2.3.8  Sponsorship and Funding 
This study received no direct sponsorship or funding however fees associated 
with undertaking an MSc were partially funded by NHS Greater Glasgow and 
Clyde staff bursary programme. The Randomised Controlled Trial was funded 
jointly as a University of Glasgow Industrial PhD Partnership with Dentsply 
Sirona.  
 
The funding below contributed to support of the cohort study,  which was also 
supported by NHS Greater Glasgow and Clyde: 
o T cells and Teeth – what do oral mucosal T cells do in health and disease The Sir 
Jules Thorn PhD Studentship. £84,000 September 2013-September 2016 
o Senior Clinical Research Fellowship. Scottish Clinical Research Excellence 
Development Scheme. £390,000 February 2012 – January 2016 
o Rheumatoid Arthritis and Periodontal Disease (RAPID). Support for Training and 
career development of researchers (Marie Curie). Networks for Initial Training. 
£200,000 S Culshaw, P Garside, I McInnes. October 2012 – September 2015 
o Protein citrullination as a link between periodontal diseases and rheumatoid 
arthritis and target for development of novel drugs. European Union FP7 ‘Health.’ 
Coordinated by University of Goteborg. Total Funding €5,800,000. Allocation to 
University of Glasgow €544,560. S Culshaw, IB McInnes, P Garside. January 2011 - 
October 2014 
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Chapter 3: Clinical Outcomes and Systemic 
Effects of Periodontal Treatment 
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3.1 Introduction 
The cornerstone of periodontal treatment is non-surgical debridement of the 
root surface (Badersten et al., 1987, Suvan et al., 2019). The two principle 
methods of providing this treatment are hand instrumentation and ultrasonic 
instrumentation. Hand instrumentation involves mechanically removing plaque 
and calculus deposits from the root surface, usually using specially designed of 
curettes (Figure 2-1, Chapter 2). Ultrasonic instrumentation is a subset of 
‘powered instrumentation techniques’ and describes the removal of plaque and 
calculus from the root surface using a rapidly vibrating stainless steel tip 
connected to a water irrigation system to keep the tip cool and flush debris from 
the operative site. The ultimate goal of both techniques is biofilm removal. In 
contemporary daily practice, clinicians often use a combination of these two 
techniques (Newman et al., 1994), solely due to personal preference or habits 
formed throughout training. This ‘combination/blended approach’ may 
therefore be regarded as ‘treatment as normal’.  
 
The clinical effectiveness of non-surgical periodontal therapy has been robustly 
explored in the periodontal literature. Both hand and ultrasonic instruments 
have strong evidence (Suvan et al., 2019, Tunkel et al., 2002) to support their 
ability to reduce local inflammation and promote positive changes in the 
subgingival environment (Mombelli, 2018) and improved clinical parameters of 
periodontal disease status (Suvan, 2005).  
 
This study aimed to investigate the clinical and systemic effects of periodontal 
treatment, comparing different instrumentation techniques.  
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3.2 Results 
3.2.1 Patient Baseline Characteristics 
The details of the studies from which the three groups of patients were obtained 
are described in Chapter 2, under Sections 2.1, Section 2.2 and Figures 2-2, 
Figure 2-3 and the process of patient selection in Section 2.3.2. 
 
A total of 55 patients were included in the current study and all were diagnosed 
with Generalised Stage III or Stage IV Periodontitis which was currently unstable 
(Papapanou et al., 2018). 42 per-cent (23 patients), 11 per-cent (6 patients) and 
47 per-cent (26 patients) of study patients were classified as Stage III Grade B, 
Stage III Grade C and Stage IV Grade C periodontitis respectively. 
 
Visual inspection of the baseline characteristics (Table 3-1) showed more 
smokers, females and higher baseline PISA in the combination group, relative to 
hand and ultrasonic groups. However, higher numbers of smokers and baseline 
disease has potential to affect clinical and systemic inflammatory outcomes of 
periodontal treatment. As described in Section 2.3.1,, a roughly equal number of 
patients to the RCT groups were chosen from the cohort study to best match 
inclusion criteria of the RCT. This led to matching first by medical history as this 
was deemed most relevant to periodontal disease outcomes (patients were 
accepted into the cohort study if generally fit and well, but some were taking 
medication deemed unlikely to impact on antibody responses such as proton 
pump inhibitors and selective serotonin reuptake inhibitors). By chance, the 
patients selected from the cohort study often happened to be males who smoke. 
No statistical testing was carried out for baseline variables in the RCT, as per 
CONSORT guidelines (http://www.consort-statement.org/). Statistical testing of 
baseline characteristics is advised against because ‘such significance tests assess 
the probability that observed baseline differences could have occurred by 
chance’; however, we already know that any differences are caused by chance 
as a result of randomization techniques. 
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Table 3-1 - Patient Baseline Characteristics 
Baseline patient characteristics. Patients are grouped according to treatment received. 
All data are displayed as Median (Q1, Q3; min - max)  
Normally distributed variables = BMI, number of teeth, PPD, Full mouth BOP, Full mouth 
Plaque, CAL, Pockets ≥5mm. Non-normally distributed variables = Current Smoker Pack 
Years, CRP, PISA.  
PPD = Periodontal Probing Depth, BOP = Bleeding on Probing, PISA = Periodontally 
Inflamed Surface Area, CAL = Clinical Attachment Loss, SD = Standard Deviation. BMI = 
body mass index, CR = C-reactive protein. 
 
 
 
Variable 
Median 
(Q1,Q3) 
(min – max) 
Hand Instruments 
(n=19) 
Ultrasonic 
Instruments 
(n=18) 
Combination 
(n=18) 
Age, years 41.3 (39.3, 49)   
(32 - 59) 
46.0 (36.8, 54.4)  
(32 - 65) 
49 (42, 49)  
(32 – 64) 
Gender, 
female n (%) 9 (47) 10 (56) 1 (6) 
Smoking, 
current n (%) 6 (32) 5 (28) 11 (61) 
Current 
Smoker Pack 
Years 
17 (16.1, 18.8) 
(15.8 – 19.5) 
10.9 (3.0, 17.8) 
(2.4 - 18) Data not collected 
BMI. Kg/m2 29.62 (23.8, 34.4) 
(20 – 39) 
27.8 (24.5, 30.0) 
(21 – 33) Data not collected 
CRP, mg/l 1.21 (0.4, 2.0) 
(0.3 – 9.9) 
1.6 (0.6, 2.5) 
(0.2 – 7.3) 
1.31 (0.7, 2.5) 
(0.2 – 5.8) 
Number of 
teeth 
27 (27.25, 30.8) 
(24 – 32) 
27.5 (24.5, 30) 
(20 – 32) 
29 (26.5, 31) 
(22 – 32) 
PPD (mm) 3.98 (3.11, 4.8) 
(2.3 – 5.7) 
3.70 (3.4, 4.1) 
(3 – 5.8) 
3.74 (3.9 – 4.4) 
(2.5 – 5.5) 
Full mouth 
BOP (%) 
45 (21.3, 69.4) 
(4.3 – 90.3) 
38.1 (21.5, 61.5) 
(14.7 – 100) 
66 (32.3, 81.8) 
(6 – 100) 
Full mouth 
Plaque (%) 
60.5 (25, 67.7) 
(8.9 – 86.5) 
45.9 (26.1, 63.3) 
(7.4 – 100) 
62.5 (45.5, 78.8) 
(20 – 92) 
CAL (mm) 4.4 (3.3, 5) 
(2.4 – 7.1) 
4.1 (3.7, 4.4) 
(3.2 – 7.5) 
4.5 (3.8, 5.4) 
(3.2 – 6.8) 
Pockets ≥5mm 
(%) 
28.9 (18.3, 51.4) 
(10.7 – 71) 
26.7 (22.1, 36.7) 
(13.1 – 68.9) 
29.5 (17.8, 48) 
(10 – 65) 
PISA 1010 (562, 2190) 
 (105.8 – 2914.9) 
957.9 (385.6, 1759.6) 
(305.6 – 3125.6) 
1277.5 (730.1, 1837.6) 
(214.5 – 3655.9) 
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3.2.2 Clinical Response to Treatment 
Data were interrogated to answer the research question: ‘What are the effects 
on clinical periodontal outcomes, measured 90 days following treatment 
(comparing baseline with day 90), for each treatment group?’. 
 
Following treatments (Figure 2-3, Chapter 2), there were consistent 
improvements in all clinical variables assessed (PISA, PPD, Pockets ≥5mm, BOP, 
plaque, CAL) in all three treatment groups, both within the RCT groups and the 
cohort study group. Within group analysis comparing pre vs 90 days post 
treatment by Wilcoxon Signed Rank test for paired data demonstrated significant 
improvements (p-values all p<0.001) in PISA, PPD, Pockets ≥5mm, BOP, Plaque 
and CAL for all three groups (Table 3-2 and Figure 3-1). The median periodontal 
probing depth reduced 0.87 (0.51, 1.38) mm, 1.0 (0.79, 1.31) mm and 0.95 
(0.46, 1.36) mm (median (Q1, Q3)) for hand instrumentation, ultrasonic 
instrumentation and combination instrumentation respectively. Rates of pocket 
closure were calculated as (defined as conversion of a pocket ≥5 mm to ≤4 mm 
following treatment) 53.16 (40.0, 77.78) %, 62.54 (50.63, 82.86) % and 70.42 
(51.84, 85.69) % (median (Q1,Q3)) for hand instrumentation, ultrasonic 
instrumentation and combination instrumentation respectively. Bleeding on 
probing (median (Q1,Q3)) reduced following treatment by 35.00 (10.92, 52.23) % 
for hand instrumentation; 28.37 (16.17, 49.32) % for ultrasonic instrumentation 
and 50.5 (28.0, 69.5) % for combination treatment. Plaque scores (median 
(Q1,Q3)) reduced significantly following treatment in all groups – 44.35 (18.10, 
51.66) %, 33.23 (15.21, 48.67) % and 42.0 (27.75, 56.75) % for hand 
instrumentation, ultrasonic instrumentation and combination instrumentation. 
Marked reductions in PISA were observed – 936.10 (304.36, 1392.59) mm2, 743.57 
(268.76, 1589.81) mm2 and 1167.35 (674.52, 1743.58) mm2 (median, Q1, Q3) for 
hand instrumentation, ultrasonic instrumentation and combination 
instrumentation respectively (Table 3-2, Figure 3-1).  
 
The absolute magnitude of change in each clinical parameter was assessed by 
subtracting Day 90 value from the Baseline value (Table 3-2). Values for 
magnitude of clinical change were similar in all three groups, with an apparent 
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trend towards improved outcomes in PISA, pocket closure, CAL and BOP for the 
combination group.  
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Variable 
Median (Q1, Q3) 
Timepoint Hand Instruments (n=19) Ultrasonic Instruments (n=18) Combination (n=18) 
PISA (mm2) 
Baseline 1010.02 (561.99, 2190.01) 957.93 (385.55, 1759.57) 1277.45 (730.13, 1837.63) 
Day 90 192.59 (59.78, 380.49) 134.85 (62.31, 219.72) 124.20 (58.80, 358.10) 
Change ↓936.10 (304.36, 1392.59) ↓743.57 (268.76, 1589.81) ↓1167.35 (674.53, 1743.58) 
Within group p-value† <0.001 <0.001 <0.001 
PPD (mm) 
Baseline 3.98 (3.11, 4.78) 3.70 (3.35, 4.12) 3.74 (3.04, 4.37) 
Day 90 3.02 (2.52, 3.73) 2.68 (2.39, 3.09) 2.77 (2.48, 3.24) 
Change ↓0.87 (0.51, 1.38) ↓1.0 (0.79, 1.31) ↓0.95 (0.46, 1.36) 
Within group p-value† <0.001 <0.001 <0.001 
Pockets ≥5mm (%) 
Baseline 28.85 (18.33, 51.39) 26.73 (22.08, 36.71) 29.5 (17.75, 48) 
Day 90 11.67 (3.89, 30.95) 10.88 (3.87, 16.88) 10.00 (3.50, 12.25) 
Change ↓17.30 (11.29, 23.21) ↓16.87 (12.83, 25.69) ↓16.5 (12.0, 34.75) 
Within group p-value† <0.001 <0.001 <0.001 
Full Mouth BOP (%) 
Baseline 45.0 (21.26, 69.44) 38.11 (21.45, 61.49) 66 (32.25, 81.75) 
Day 90 8.33 (2.98, 13.10) 8.10 (4.12, 12.08) 8.5 (3.75, 18.00) 
Change ↓35.00 (10.92, 52.23) ↓28.37 (16.17, 49.32) ↓50.5 (28.0, 69.5) 
Within group p-value† <0.001 <0.001 <0.001 
Full Mouth Plaque (%) 
Baseline 60.48 (25.0, 67.74) 45.92 (26.1, 63.33) 62.5 (45.5, 78.75) 
Day 90 8.33 (4.17, 14.06) 7.80 (3.50, 13.25) 13.00 (7.75, 28.5) 
Change ↓44.35 (18.10, 51.66) ↓33.23 (15.21, 48.67) ↓42.0 (27.75, 56.75) 
Within group p-value† <0.001 <0.001 <0.001 
CAL (mm) 
Baseline 4.36 (3.29, 5.02) 4.14 (3.66, 4.43) 4.51 (3.8, 5.38) 
Day 90 4.01 (3.03, 4.68) 3.63 (3.10, 4.12) 3.42 (2.81, 4.14) 
Change ↓0.36 (0.05, 1.12) ↓0.52 (0.26, 0.80) ↓1.03 (0.72, 1.51) 
Within group p-value† <0.001 <0.001 <0.001 
†Differences between baseline and day 90 within groups tested using Wilcoxon signed rank test.      (Table legend overleaf) 
 
Table 3-2 – Clinical Parameters of Periodontitis Pre and Post Treatment  
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Table 3-2 – Clinical Parameters of Periodontitis Pre and Post Treatment  
Clinical measures of periodontitis disease state for baseline and Day 90 following treatment.  
Patients are grouped according to treatment received.  
Magnitude of improvement in clinical measures of periodontitis disease state following treatment are shown in the ‘Change’ row.  
All data are presented as Median (Q1, Q3) and are relative to baseline measurements, apart from pocket closure % (defined as percentage of 
pockets being converted from ≥5mm probing depth to ≤4mm probing depth following treatment).  
Arrows denote direction of change – calculated by subtracting pre-treatment value of variable from post treatment value. 
 
 
 
 
 
 
Table 3-2 – Clinical Parameters of Periodontitis Pre and Post Treatment 
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Figure 3-1 - Clinical Outcomes of Periodontal Treatment 
Patients were treated with exclusively hand instruments (grey bars, n = 19), exclusively 
ultrasonic instruments (dotted bars, n = 18) or a combination of both instruments 
(white bars n = 18). PISA was recorded before and 90 days after treatment.  
*** = p<0.001 comparing pre and post treatment within each group by Wilcoxon Signed 
Rank Test for related samples. Data are presented as Tukey Box Plots (horizontal bar 
shows median, + shows mean, whiskers show minimum and maximum and circles show 
outliers as separate data points). 
A – PISA; B – PPD; C – Total Pockets ≥5mm; D – CAL; E – BOP; F – Plaque  
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3.2.3  Clinical response between treatment groups and the effect 
of confounding variables 
To address the research questions of ‘Is there a difference in clinical outcome 
between treatment groups?’ and ‘How is clinical outcome affected by particular 
key confounders?’, a data modelling approach was adopted. 
 
As detailed in Section 2.3.7 (Chapter 2), General Linear Models were devised to 
investigate the effect of different treatment groups on clinical outcomes 
considering confounding variables of relevance to periodontal disease and its 
treatment – such as smoking status, level of baseline disease and number of 
teeth. The most basic model included no confounders. Models were then created 
incorporating baseline levels of disease and sequentially more confounding 
variables. Parameter estimates (ß values) between treatment groups were used 
to assess the impact such variables had on clinical outcomes, relative to the 
preceding model. Parameter estimates (ß values) represent the change in 
standard deviations of an outcome variable (e.g. periodontal pocket depth) 
when a one standard deviation change is made to the predictor variable. ß 
values were used as a means to help quantify the effect confounders had upon 
the outcome of interest (when compared to the preceding model’s parameter 
estimate value). Due to the variety of variables and multiple variables using Ln 
data (all but PPD and CAL), a universally applicable ‘clinically relevant’ change 
in ß value cannot be suggested.  
 
Table 3-3 reports the findings from the General Linear Models described in 
Section 2.3.7 and compared the two arms of the RCT in the first instance, then 
compared across the three treatment groups. There is little difference between 
the two groups in the RCT nor the three groups in the combined study for any of 
the follow-up clinical measures for Model 1 (unadjusted). These differences did 
not alter after adjustment for baseline measures or any of the relevant 
confounding variables (Models 2 – 5). The exception was for CAL (clinical 
attachment level). However, this is likely to be a spurious result - as more 
stringent modelling (Models 3, 4 and 5) did not repeat this finding consistently. 
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Model 2 (Table 3-3) was adjusted for baseline levels of disease. ß values for the 
difference between treatment groups were minimally affected. For example, 
when considering PISA, the parameter estimates (ß values) of hand 
instrumentation vs ultrasonic instrumentation and hand instrumentation vs 
combination instrumentation increased by 0.026 and 0.186 respectively (with 
respect to the ß value when using the unadjusted model) (Table 3-3). Overall, 
relative changes in parameter estimates (Ln transformed data) were in the 
region of 0.006 to 0.140 across all clinical variables assessed when baseline 
levels of disease were included in modelling. This analysis suggests minimal 
differences in clinical outcomes between treatment groups when baseline 
disease severity was taken into account. 
 
A greater change in parameter estimate was demonstrated when further 
adjustment was made for smoking status (Model 3), particularly comparing hand 
instrumentation and combination instrumentation. For total pockets ≥5mm, ß 
increased from -0.372 to 0.793 – a change of 1.165. When adjusting for levels of 
smoking, parameter estimates for all clinical variables changed with greatest 
magnitude, compared to any other confounder. This effect was most apparent in 
the combination group. This analysis suggests smoking was the most influential 
confounding factor for treatment outcome within the current study and the 
finding of the greatest effect in the combination group may relate to the 
comparatively higher number of smokers, compared to other groups.  
 
When further adjusting for treatment time, parameter estimate changes were 
noted in the region of 0.004 to 0.200 across all clinical variables considered. 
With further adjustments for age, gender, and number of teeth, similar, low 
magnitude changes were noted across all clinical variables (Table 3-3). These 
low magnitude changes were similar across all treatment groups and in real 
terms suggests a minimal, likely negligible influence of these confounding 
factors on clinical outcomes factors. 
 
There were similar clinical outcomes (pre vs post treatment) (indicated by PISA, 
PPD, pockets ≥5mm, BOP, plaque, CAL) in all groups, assessed by fully adjusted 
general linear model - all p values >0.05 (Table 3-3). However, caution is 
 
 
 
75 
advised in interpretation of this finding as both the RCT and the current study 
were not specifically powered to detect differences or equivalence in clinical 
variables. 
 
In summary, results would suggest smoking had the greatest effect on 
differences between treatment groups, for the majority of clinical variables – 
compared to other confounders. This result is expected as it is well reported 
smoking is a significant factor in clinical response to periodontal treatment. This 
effect was most apparent within the combination treatment group - this group 
had the greatest number of patients who smoke and may explain therefore this 
result.  
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Table 3-3 – Clinical Outcomes Between Treatment Groups   
 Model 1 Model 2 Model 3 Model 4 Model 5 
PISA      
Hand 0 (reference) 0 (reference) 0 (reference) 0 (reference) 0 (reference) 
Ultrasonic ß (95% CI) -0.164 (-0.942 to 0.613) -0.138 (-0.783 to 0.507) 0.070 (-1.100 to 1.240) 0.076 (-1.117 to 1.269) -0.074 (-1.585 to 1.436) 
Combination ß (95% CI) -0.031 (-0.808 to 0.747) -0.217 (-0.867 to 0.432) 0.788 (-1.452 to 3.028) 0.786 (-1.481 to 3.053) 1.099 (-1.438 to 3.635) 
p-value (H vs U) 0.691 0.676 0.791 0.406 0.593 
p-value (H vs U vs C) 0.905 0.793 0.946 0.963 0.856 
PPD*      
Hand 0 (reference) 0 (reference) 0 (reference) 0 (reference) 0 (reference) 
Ultrasonic ß (95% CI) -0.277 (-0.703 to 0.149) -0.225 (-0.481 to 0.032) -0.172 (-0.631 to 0.288) -0.144 (-0.610 to 0.322) -0.208 (-0.793 to 0.377) 
Combination ß (95% CI) -0.231 (-0.701 to 0.151) -0.143 (-0.399 to 0.114) 0.343 (-0.532 to 1.219) 0.333 (-0.546 to 1.212) 0.302 (-0.664 to 1.268) 
p-value (H vs U) 0.179 0.099 0.138 0.246 0.095 
p-value (H vs U vs C) 0.378 0.212 0.247 0.418 0.394 
Total pockets≥5mm      
Hand 0 (reference) 0 (reference) 0 (reference) 0 (reference) 0 (reference) 
Ultrasonic ß (95% CI) -0.237 (-0.935 to 0.461) -0.230 (-0.760 to 0.299) -0.034 (-0.999 to 0.932) 0.053 (-0.920 to 1.026) -0.080 (-1.602 to 1.442) 
Combination ß (95% CI) -0.400 (-1.098 to 0.298) -0.372 (-0.901 to 0.158) 0.793 (-1.054 to 2.641) 0.748 (-1.094 to 2.589) 1.075 (-1.481 to 3.630) 
p-value (H vs U) 0.297 0.265 0.309 0.279 0.104 
p-value (H vs U vs C) 0.515 0.368 0.694 0.837 0.636 
(continued) 
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Table 3-3 continued 
 
Table legend overleaf 
 Model 1 Model 2 Model 3 Model 4 Model 5 
Full Mouth BOP %      
Hand 0 (reference) 0 (reference) 0 (reference) 0 (reference) 0 (reference) 
Ultrasonic ß (95% CI) 0.053 (-0.572 to 0.677) -0.005 (-0.521 to 0.511) 0.010 (-0.930 to 0.950) -0.014 (-0.972 to 0.944) -0.183 (-1.393 to 1.027) 
Combination ß (95% CI) 0.184 (-0.440 to 0.809) -0.085 (-0.612 to 0.441) 0.575 (-1.279 to 2.428) 0.589 (-1.285 to 2.463) 0.675 (-1.406 to 2.756) 
p-value (H vs U) 0.869 0.946 0.917 0.687 0.687 
p-value (H vs U vs C) 0.832 0.937 0.979 0.954 0.715 
Full Mouth Plaque %      
Hand 0 (reference) 0 (reference) 0 (reference) 0 (reference) 0 (reference) 
Ultrasonic ß (95% CI) -0.082 (-0.841 to 0.677) 0.006 (-0.732 to 0.743) -0.240 (-1.568 to 1.089) -0.439 (-1.707 to 0.829) -0.248 (-1.949 to 1.452) 
Combination ß (95% CI) 0.335 (-0.424 to 1.093) 0.176 (-0.571 to 0.923) 0.199 (-2.279 to 2.678) 0.141 (-2.205 to 2.488) 0.223 (-2.580 to 3.025) 
p-value (H vs U) 0.804 0.910 0.865 0.371 0.396 
p-value (H vs U vs C) 0.518 0.873 0.980 0.541 0.595 
CAL*      
Hand 0 (reference) 0 (reference) 0 (reference) 0 (reference) 0 (reference) 
Ultrasonic ß (95% CI) -0.246 (-0.895 to 0.403) -0.136 (-0.477 to 0.206) 0.038 (-0.577 to 0.654) 0.030 (-0.601 to 0.661) -0.072 (-0.861 to 0.717) 
Combination ß (95% CI) -0.413 (-1.062 to 0.236) -0.571 (-0.913 to -0.228) -0.459 (-1.61 to 0.688) -0.461 (-1.622 to 0.699) -0.228 (-1.531 to 1.075) 
p-value (H vs U) 0.467 0.459 0.508 0.595 0.125 
p-value (H vs U vs C) 0.443 0.004 0.082 0.111 0.194 
 
 
 
78 
 
 
 
Table 3-3 – Clinical Outcomes Between Treatment Groups - General Linear Modelling 
Parameter estimates with 95% confidence intervals and p -values for ultrasonic instrumentation compared with hand instrumentation, compared with 
combination treatment following treatment. 
Hand Instrumentation Group = reference group for General Linear Modelling 
Model 1: Unadjusted 
Model 2: Adjusted for baseline levels of clinical variable  
Model 3: Adjusted for baseline levels of clinical variable and smoking status 
Model 4: Adjusted for baseline levels of clinical variable, smoking status, treatment time, 
Model 5: Adjusted for baseline levels of clinical variable, smoking status, treatment time, age, gender, number of teeth. 
Ln data used throughout unless denoted by *, in which case non-transformed data used 
Categorical variables (treatment group, smoking status, gender) assigned as Fixed Factors 
Continuous variables (clinical variables [baseline and day 90], treatment time, number of teeth) assigned as Covariates 
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3.2.4  Treatment Time in Hand vs Ultrasonic treatment groups 
Previous studies document faster treatment with ultrasonic instruments (Tunkel 
et al., 2002, Laurell, 1990, Yukna et al., 1997, Breininger et al., 1987). 
Therefore, the research question ‘Are there differences in the time taken for 
treatment according to treatment group?’ was considered by the following 
analysis. The time to complete treatment was evaluated by measuring the time 
spent instrumenting the tooth and root surfaces, measured from the point of 
first contact of an instrument onto a tooth/root surface. Data for precise time of 
instrumentation were available only for hand and ultrasonic groups; comparable 
data were not available for the combination treatment group. The data were 
normally distributed in both groups.  
 
The total treatment time was less using ultrasonic instruments alone compared 
with using hand instruments alone (Figure 3-2). The Mean (SD) treatment time 
for hand instrumentation was 96.9 (23.08) minutes. The Mean (SD) treatment 
time for ultrasonic instrumentation was 75.39 (17.82) minutes. This reduction 
was shown to be statistically significant by independent sample 2 tailed t-test 
(p<0.003 (mean difference: 21.51 minutes; 95% CI 9.22 to 34.62)). Ultrasonic 
instrumentation required less time to complete treatment in this study. 
Ultrasonic instrumentation treatment time had a narrower range of values 
compared to hand instrumentation, as suggested by its marginally lower 
standard deviation. 
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Figure 3-2 - Treatment Time 
Patients were treated with exclusively hand instruments (grey bar, n = 19), exclusively 
ultrasonic instruments (dotted bar, n = 18). Data for combination treatment were not 
available. Box and whisker plot displaying values for time taken to complete 
periodontal instrumentation, measured in minutes, with respect to instrumentation 
technique.  Mean (+), median, Q1, Q3, Min and Max data are presented. ** = p<0.01 
(95% CI 9.22 – 34.62) by independent sample t-test 
 
 
  
Ha
nd
Ul
tra
so
nic
0
50
100
150
200
Treatment Time (minutes)
Tr
ea
tm
en
t T
im
e 
(m
in
ut
es
)
Treatment Time
Hand
Ultrasonic
✱✱
 
 
 
81 
To investigate the interaction of treatment time and disease severity (ie PISA), 
the data were subgrouped by instrumentation type and separate correlation 
coefficients (Pearson) were calculated. A Scatter plot was produced to show the 
association graphically. Hand instrumentation treatment time correlated 
positively with disease severity (r=0.62) whereas there was a less pronounced 
relationship between disease severity and treatment time using ultrasonic 
instruments (r=0.33). Similarly, time taken for hand instrumentation correlated 
with the proportion of pockets ≥5mm (Figure 3-3B) (r=0.76). Correlation 
between proportion of pockets ≥5mm and time taken to complete ultrasonic 
debridement (Figure 3-3) was r=0.271. Ultrasonic treatment therefore, on 
average, required less time to complete treatment than hand instrumentation, 
and the time saving with ultrasonic use appears proportionally greater for more 
severe disease; however, this conclusion is based on a subgroup analysis, with 
inherent limitations.   
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Figure 3-3 - Treatment Time vs Baseline Severity of Inflammation  
Patients were treated with exclusively hand instruments (grey dots, n = 19), exclusively 
ultrasonic instruments (white squares, n = 18). Data for treatment time for 
combination treatment was not available. 
Scatter plot of Baseline Disease Severity (measured by Baseline PISA) vs Treatment 
time and Baseline Pockets ≥5mm. Each dot represents a single patient.  
Lines of best fit are illustrated. 
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3.2.5 Measures of Clinical Success  
Clinical results observed within the current study were then considered in the 
context of published criteria of ‘success’ in periodontal treatment and address 
the research question ‘Was treatment for study patients successful in the 
context of published criteria of a successful outcome of periodontal treatment?’ 
A literature search was carried out to identify published criteria used to assess 
the clinical ‘success’ of periodontal therapy. In clinical practice, clinical 
outcomes in periodontal therapy are objectively measured using parameters 
such as PPD, pocket closure rates, plaque scores and bleeding on probing scores. 
Criteria were chosen for inclusion if the criteria were published in peer reviewed 
journals, and the parameters they used were in regular clinical use within our 
institution.  
 
The number of patients in each treatment group who fulfilled all or part of the 
different published criteria varied considerably depending on the criteria (Table 
3-4). No patients in any treatment group fulfilled the SDCEP (Scottish Dental 
Clinical Effectiveness Programme, 2014), criteria in full. The ‘all sites PPD 
<4mm’ goal was not met by any patient, whereas a plaque percentage of <10% 
was achieved by over 50% of patients in all groups. For other success criteria, 
just over half of all patients achieved 57% pocket closure (Suvan, 2019); 38% 
achieved the <25% BOP and <8 sites of PPD ≥5mm (Lang and Tonetti, 2003); only 
16% achieved ≤4 sites with PPD ≥5mm (Feres). When evaluating BOP at a 10% 
threshold, there appeared to be differences between the groups with eleven 
patients achieving this criterion in the combination group, but only two in the 
hand instrument group and none in the ultrasonic group. Otherwise, there were 
no clear differences between the groups (Table 3-4).  Mean pocket closure 
values were similar in the current study to the most recent systematic review on 
the subject of periodontal treatment outcomes. Overall the data indicate 
reduction in PPD as the most challenging aspect to achieve, with plaque and BOP 
values being more readily attainable for patients in this study. It should be noted 
that the patients in this study in some cases received further specialist 
treatment – the data evaluated are following initial non-surgical treatment only.  
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To visually assess how individual study patients performed with respect to 
success criteria, a schematic was created to categorise patients dichotomously 
into ‘responder’ or ‘non-responder’ status (Figure 3-4). Some additional 
‘success’ criteria ((Hughes et al., 2006), (Bizzarro et al., 2016), (Eick et al., 
2017),(Greenwood et al., 2020)) are included in Figure 3-4. Unlike those in Table 
3-4, these additional criteria have not been widely adopted clinically. However, 
they were included to provide further points of reference to assess outcomes in 
the current study. There was clear variability in responder status when 
comparing published success criteria, evaluated by individual patient. All 
patients fulfilled Greenwood 2020 (Greenwood et al., 2020) and no patients 
fulfilled pocket depth criteria from SDCEP (Scottish Dental Clinical Effectiveness 
Programme, 2014) (Figure 3-4). 
  
 
 
 
85 
  
 
Table 3-4 – Measures of Clinical Success following Periodontal Treatment 
Overview 
Number of patients from respective treatment arms of the current analysis achieving 
aspects of published periodontal clinical success criteria.  
 
Published criteria of ‘success’ following treatment for periodontal disease: 
Feres 2020 (Feres et al., 2020) 
Lang and Tonetti 2003 (Lang and Tonetti, 2003) (modified) 
Suvan 2019 (Suvan et al., 2019) 
Scottish Dental Clinical Effectiveness Programme 2014 (Programme, 2014) 
*Full study data set 
 
Success 
Criteria 
Constituents 
of Success 
Criteria 
Hand 
Instrumentation 
(n=19) 
Ultrasonic 
Instrumentation 
(n=18) 
Combination 
Instrumentation 
(n=18) 
Total 
Fulfilling 
All 
Criteria* 
(n= 55) 
Feres  
 
≤4 sites with 
PPD ≥5mm 
2 3 4 9 (16%) 
Lang 
and 
Tonetti  
<8 sites of 
PPD ≥5mm 
7 5 4 
21 (38%) 
<25% BOP 17 17 16 
Suvan  
Mean 57% 
pocket 
closure 
9 10 12 31 (55%) 
SDCEP  
Plaque <15% 16 15 11 
0 (0%) 
BOP <10% 2 0 11 
All sites 
<4mm PPD 
0 0 0 
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Figure 3-4 – Measures of Clinical Success following Periodontal Treatment  
Schematic representation of patients (separated by study) within the current analysis assessed against published periodontal clinical success criteria.  
Connecting lines across the right y-axis associate published criteria inspired by one another. 
Each column represents a single patient. If a patient is a ‘Responder’ with respect to the success criteria, a shaded rectangle is shown. Individual patient response status across 
criteria can be assessed by following y-axis.  
Published criteria of ‘success’ following treatment for periodontal disease: 
Feres 2020 (Feres et al., 2020)  - ≤4 sites with PPD ≥5mm; Lang and Tonetti 2003 (Lang and Tonetti, 2003) (modified) - <8 sites of PPD ≥5mm and <25% BOP; Suvan 2019 (Suvan et al., 2019) - 
Mean 57% pocket closure; Scottish Dental Clinical Effectiveness Programme 2014 (Programme, 2014) - Plaque <15%, BOP <10%, All sites <4mm PPD; Hughes 2006 (Hughes et al., 2006) - ≥30% 
responding sites. Responding sites are those ≥5mm at BL which decreased by 2mm; Eick 2017 (Eick et al., 2017) - 60% reduction in pockets >4mm; Greenwood 2020 (Greenwood et al., 2020) - ≥25% 
responding sites. Responding sites are those ≥5mm at BL which decreased by 2mm; Bizarro 2016 (Bizzarro et al., 2016) - Above median pocket closure rate 
6 11 12 15 16 21 24 25 28 31 33 36 37 38 41 43 44
Patient ID (PExx)
Combination Instrumentation
2 3 7 11 12 13 14 20 22 24 26 29 30 32 34 37 38 39 41 4 5 8 9 10 15 16 18 19 21 23 25 27 28 31 33 35 42
SDCEP (plaque)
SDCEP (bleeding)
SDCEP (pocket depth)
Lang and Tonetti, 2003
Hughes et al., 2006
Bizzarro et al., 2016
Eick et al., 2017
Suvan et al., 2019†
Feres et al., 2020
Greenwood et al., 2020
Patient ID (IRxx)
Hand Instrumentation Ultrasonic Instrumentation
 
 
 
 
 
 
3.2.6 Effect of periodontal treatment on systemic inflammation  
In addition to exploration of clinical outcomes of periodontal treatment, the 
systemic effects were considered by evaluating serum hsCRP. Specific research 
questions considered included ‘Does CRP immediately increase following 
periodontal treatment?’ and ‘Is there a difference between treatment groups 
with respect to changes in CRP levels at day 90 post-treatment?’ The immediate 
post treatment change in CRP was only evaluated in the RCT, therefore there 
were no data for immediate changes in CRP in the combination group. 
 
Serum CRP was evaluated at baseline, day 1, day 7 and day 90 in the RCT, and at 
baseline and day 90 in the cohort study (Figure 2-3, Chapter 2). Serum CRP 
increased significantly at Day 1 following treatment across all patients in hand 
and ultrasonic treatment groups (Table 3-5 and Figure 3-5, Wilcoxon Signed Rank 
Test, 2-tailed p value = 0.008) compared to baseline levels.   
 
Following the increase at Day 1, serum CRP in both hand and ultrasonic 
instrumentation groups reduced, initially at Day 7 and further at Day 90 to 
approximately baseline levels (Figure 3-5). Changes in CRP levels in hand vs 
ultrasonic treatment groups were of a comparable, albeit low, magnitude (Table 
3-5). Median (Q1,Q3) CRP for the hand instrumentation group reduced by 0.06 (-
0.56, 0.48). Median (Q1,Q3) CRP for the ultrasonic instrumentation group 
reduced by 0.15 (-0.07, 1.29) and median (Q1,Q3) CRP for combination 
treatment increased by 0.08 (-0.72, 0.41) at Day 90 follow up.  
 
The magnitude of differences in CRP measured at Day 90 between treatment 
groups was minimal (Table 3-5). Across all patients, at Day 90 follow up, CRP 
levels were not significantly different compared to baseline (by performing 
paired t-test using Ln transformed data; mean difference = 0.216; p = 0.085, 95% 
CI = -0.03 to 0.46).  
 
Furthermore, following adjustment for baseline levels of CRP, sex, age, smoking 
status, BMI at baseline and treatment time, in a multivariable model no 
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statistically significant differences were observed between treatment groups 
(p=0.125) (Table 3-6). This absence of difference is also seen in separate general 
linear modelling, comparing hand and ultrasonic treatment groups in isolation 
(p=0.28, 95% CI -0.259 to -0.867). The 95% confidence interval for this finding 
demonstrates a fairly imprecise result. These results therefore suggest some 
minor variation in changes in CRP ninety days following periodontal treatment, 
across the three treatment groups. Caution in interpretation is warranted due to 
lack of specific statistical powering for differences in CRP at day 90.  
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Table 3-5 – Serum C-reactive Protein (mg/L) 
Patients were treated with exclusively hand instruments (n = 19), exclusively ultrasonic 
instruments (n = 18) or a combination of both instruments (n = 18). 
Median (Q1, Q3) data are displayed, as data were non-normally distributed.  
C-reactive protein titre is displayed at each study time point. Reduction in CRP is also 
shown – please note no statistical tests were carried out using change data.  
 
 
 
 
 
INSTRUMENTATION 
TECHNIQUE 
HAND 
INSTRUMENTS 
ULTRASONIC 
INSTRUMENTS 
COMBINATION 
BASELINE 1.21 (0.44, 2.03) 1.60 (0.62, 2.49) 1.31 (0.69, 2.47) 
DAY 1 1.78 (0.99, 3.96) 2.57 (1.02, 3.86) No Data 
DAY 7 1.88 (0.71, 3.20) 0.97 (0.51, 2.74) No Data 
DAY 90 1.28 (0.54, 2.34) 0.72 (0.44, 1.12) 1.36 (0.58, 2.55) 
CRP CHANGE 
PRE VS 90 DAYS 
POST TREATMENT 
↓0.06 (-0.56 – 0.48) ↓0.15 (-0.07, 1.29) ↑0.08 (-0.72, 0.41) 
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Table 3-6: Parameter estimates with 95% confidence intervals for inter-group differences for ln-transformed serum C-reactive 
Protein at day 1, day 7 and day 90.  
 
 Day 1 Day 7 Day 90 
β 95% CI p-value β 95% CI p-value β 95% CI p-value 
C-Reactive protein (Hand instruments vs Ultrasonic Instruments) 
Model 1† 0.143 -0.582 to 0.867 0.69 0.271 -0.553 to 1.09 0.51 0.518 -0.202 to 1.239 0.15 
Model 2‡ 0.130 -0.369 to 0.628 0.60 0.311 -0.329 to 0.950 0.33 0.482 -0.073 to 1.038 0.09 
Model 3§ 0.293 -0.221 to 0.810 0.30 0.231 -0.510 to 0.972 0.53 0.304 -0.259 to 0.867 0.28 
C-Reactive protein (Hand instruments vs Ultrasonic Instruments vs Combination Instruments) 
Model 1† Hand - - - - - - 0 (ref) 0 (ref) 
0.239  Ultrasonic - - - - - - -0.518 -1.231 to 0.195 
 Combination - - - - - - 0.032 -0.671 to 0.734 
Model 2‡ Hand - - - - - - 0 (ref) 0 (ref) 
0.141  Ultrasonic - - - - - - -0.480 -1.019 to 0.058 
 Combination - - - - - - -0.012 -0.542 – 0.519 
Model 3§ Hand - - - - - - 0 (ref) 0 (ref) 
0.125  Ultrasonic - - - - - - -0.335 -1.462 to 0.792 
 Combination - - - - - - 0.958 -0.863 to 2.780 
Table legend overleaf 
90 
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Table 3-6: Parameter estimates with 95% confidence intervals for inter-group 
differences for ln-transformed serum C-reactive Protein at day 1, day 7 and 
day 90.  
 
Results of General Linear Modelling comparing levels of serum CRP across treatment 
groups as indicated at follow up time points, explored within three models. 
 
No data available for Day 1 or Day 7 CRP levels for combination treatment. 
 
‘-‘ denotes no available data.  
 
†Model 1: Unadjusted.  
‡Model 2: Adjusted for baseline levels of CRP.  
§Model 3: Adjusted for baseline levels of CRP, sex, age, smoking status, BMI at baseline 
(only used for RCT data as not collected for cohort study) and treatment time. 
 
β-values are on the ln-transformed scale  
 
Categorical variables (sex, age, smoking status) assigned as fixed factors 
Continuous variables (CRP, BMI at baseline, treatment time) assigned as covariates 
 
Hand instrumentation assigned as reference variable for all testing
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Figure 3-5 - Changes in Serum C-reactive Protein at day 1, day 7 and day 90 
following treatment 
Patients were treated with exclusively hand instruments (grey, n = 19) or exclusively 
ultrasonic instruments (dotted, n = 18). Box and whisker plot displaying values for CRP 
titre across all study time points. 
Data are presented as Tukey Box Plots (horizontal bar shows median, + shows mean, 
whiskers show minimum and maximum and circles show outliers as separate data 
points. 
Please see Table 3-5 for raw data 
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Figure 3-6 – Serum C-reactive Protein at baseline and 90 days post treatment 
Patients were treated with exclusively hand instruments (grey bars, n = 19), exclusively 
ultrasonic instruments (dotted bars, n = 18) or a combination of both instruments 
(white bars n = 18). 
Box and whisker plot displaying values for CRP titre with respect to instrumentation 
technique.  
Data are presented as Tukey Box Plots (horizontal bar shows median, + shows mean, 
whiskers show minimum and maximum and circles show outliers as separate data 
points. 
Please see Table 3-5 for raw values 
 
 
 
  
Ba
se
lin
e
Da
y9
0
Ba
se
lin
e
Da
y9
0
Ba
se
lin
e
Da
y9
0
0.0
1.5
3.0
4.5
6.0
7.5
9.0
10.5
12.0
Time Point
C
R
P(
m
g/
L)
CRP- Pre vs Post Treatment
Hand
Ultrasonic
Combination
 
 
 
 
94 
3.3 Discussion 
The data presented in this chapter show periodontal treatment, regardless of 
instrumentation approach, resulted in significant clinical improvements. 
Previous studies have compared hand and ultrasonic, but few have included any 
comparison with ‘blended’ or ‘combination’ approaches – the latter being the 
most commonly used in clinical practice.  
The data demonstrate that systemic inflammation  - evaluated by serum hsCRP - 
increases one day following full mouth debridement, irrespective of instrument 
choice; and that serum CRP serum returned to approximately baseline levels at 
day 90 following treatment. No differences were observed in day 90 levels of 
CRP comparing treatment groups. 
Non-surgical periodontal treatment clinical effectiveness was recently assessed 
in a systematic review (Suvan et al., 2019) which analysed 18 studies across a 
trio of ‘PICO’ questions – one of which involved the comparison of hand and 
ultrasonic instruments for subgingival instrumentation in the context of 
generalised periodontitis. This systematic review found no statistically 
significant differences between the two techniques, with a weighted periodontal 
probing depth reduction of 1.7 mm at approximately 6 months follow up (for 
combination treatment; 11 studies analysed). The current study reported median 
(Q1,Q3) periodontal probing depth changes of 0.87 (0.51, 1.38) mm, 1.0 
(0.79,1.31) mm and 0.95 (0.46, 1.36) mm for hand instrumentation, ultrasonic 
instrumentation and combination instrumentation respectively. This observed 
difference between the data presented here and the systematic review may 
relate to follow up periods differing between 90 days (current study) and 6 
months (systematic review). This difference may be significant as it has been 
established collagen maturation and further reduction in periodontal probing 
depth has potential to continue over at least a 6-month period (Stanton et al., 
1969) – with the effect of gaining further clinical improvements. There may also 
be variations in population studied, baseline disease severity or data collection 
methods. Overall, it seems most likely that a follow up of 90 days may be too 
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soon to assess definitive changes in mean periodontal probing depths following 
non-surgical periodontal therapy. 
With respect to clinical attachment level (CAL), the current study showed a 
significant improvement following treatment with all treatment approaches 
(p<0.01) (Figure 3-1F) and a CAL change (median (Q1,Q3) shown) of 0.36 (0.05, 
1.12) mm, 0.52 (0.26, 0.80) mm and 1.03 (0.72, 1.51) mm for hand 
instrumentation, ultrasonic instrumentation and combination treatment 
respectively. A recent systematic review on efficacy of non-surgical periodontal 
treatment (Smiley et al., 2015) reported a mean CAL change of approximately 
0.5mm following treatment, similar to the current study’s findings. 
 
In the current study, plaque and bleeding on probing both significantly reduced 
following all treatments provided, with median (Q1,Q3) reductions in plaque of 
44.35 (18.10, 51.66) %, 33.23 (15.21, 48.67) % and 42.0 (27.75, 56.75) % and 
median (Q1, Q3) reductions in bleeding on probing of 35.00 (10.92, 52.23) %, 
28.37 (16.17, 49.32) % and 50.5 (28.0, 69.5) % for hand instrumentation, 
ultrasonic instrumentation and combination instrumentation respectively. This is 
again in line with published evidence on the expected clinical outcomes 
following non-surgical periodontal therapy of an overall reduction in percentage 
of sites exhibiting bleeding on probing and improvements in full mouth plaque 
scores (Smiley et al., 2015, Suvan et al., 2019). 
 
Smoking was shown as the most influential confounder with respect to effects on 
clinical periodontal parameters in the current study. This effect was most 
notable for treatment using combination instruments (Table 3-3). An explanation 
of this finding is likely the comparatively high number of smokers in this 
treatment group. However, the finding of smoking having a large effect upon 
clinical parameters is in line with published evidence (Bergstrom et al., 1991, 
Bergstrom et al., 2000, Haffajee and Socransky, 2001, Leite et al., 2018). 
Notably fewer females were present in the combination group compared to 
other groups studied (Table 3-1). When adjusting for Gender (with age and 
number of teeth), minimal parameter estimate changes were seen – suggesting 
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gender, age and number of teeth were not significant in affecting outcome of 
periodontal treatment (Table 3-3). 
 
Periodontal inflamed surface area (PISA) has been suggested to correlate with 
other measures of periodontal disease severity. (Park et al., 2017, Nesse et al., 
2008, Leira et al., 2018). For example, Leira et al showed PISA was lowest in 
periodontal healthy individuals at values of 34.30 ± 16.48 mm2 and highest in 
cases of severe periodontitis (as per Centres for Disease Control and Prevention 
and American Academy of Periodontology classification of periodontitis cases 
(Page and Eke, 2007)) with values of 2309.42 ± 587.69 mm2. Patients in the 
current study (across all treatment groups) had a median (Q1, Q3) PISA level of 
1087.91 mm2 (561.99, 1899.20). This value is perhaps rather low, however, 
would still be classified as ‘severe periodontitis’, according to Leira 2018 as 
‘severe periodontitis’ was found to include a range of values from 934.71 mm2 to 
3274.96 mm2. This finding may be due to patients in this study having received 
basic periodontal care previously by their general dentist, prior to inclusion in 
the current analysis. Furthermore, if a site does not bleed (even if increased 
probing depth is present), this site will not ‘count’ towards the PISA calculation 
which will also affect the calculated PISA value. PISA however serves as a useful 
amalgamation of multiple clinical indicators of periodontal disease. It was 
demonstrated (Figure 3-1A) that all treatment approaches resulted in significant 
reductions in PISA (p<0.001) following treatment (Table 3-2).  
 
To compare clinical parameters between treatment groups at day 90 post 
treatment, Univariate General Linear Models were created controlling for 
successively more confounding variables. Non-parametric data were commonly 
identified within Day 90 data sets. This finding is likely due to the previously 
described differential in response of single and multirooted teeth to non-surgical 
periodontal treatments (Suvan et al., 2019, Badersten et al., 1987, Hamp et al., 
1975), leading to a skew in the data. Models created required normally 
distributed data and as described, some variables in the current analysis 
required transformation and this is therefore a potential limitation of the study. 
Alternative non-parametric testing such as Friedman test (for paired data) may 
have been useful. It was established that improved clinical outcomes were 
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comparable across all treatments, regardless of clinical variable used for 
assessment (Table 3-3). This finding was consistently present from the 
unadjusted model to the fully adjusted model. However, results of statistical 
testing must be interpreted with caution in the current study as the RCT (hand 
and ultrasonic treatment groups) was powered only to detect differences in CRP 
at day 1.  
 
The similar response to treatment in each treatment group (Table 3-2, Table 3-
3) was expected given current knowledge of clinical equivalence between hand 
and ultrasonic instruments (Tunkel et al., 2002, Suvan et al., 2019). As 
expected, combination treatment also resulted in broadly similar clinical 
outcomes. However, a suggestion of a trend towards marginally more favourable 
outcomes in the combination treatment group is present in illustrated ‘change’ 
data (Table 3-2). For example, median pocket closure rate for combination was 
70.42 %, compared to 53.16 % and 62.54 % for hand and ultrasonic 
instrumentation respectively. A similar trend is displayed in BOP, plaque and CAL 
values – all favouring combination treatment by a small but noticeable margin. 
An explanation for this finding may lie in higher baseline levels of periodontal 
disease in the combination group (Table 3-1) (for example – baseline PISA in the 
combination group = 1277.45 mm2, compared to 1010.02 mm2 and 957.93 mm2 in 
hand and ultrasonic groups at baseline) – thus leading to a more pronounced 
response to treatment, as is expected in more severe cases (Cobb, 2002, Smiley 
et al., 2015, Suvan et al., 2019). Furthermore, Cobb 2002 reported with initial 
probing depths of 4-6mm a 1.29mm mean PPD reduction; whereas initial probing 
depths of >7mm led to 2.16mm mean PPD reduction following non-surgical 
periodontal therapy. A larger study would be required to further investigate 
whether there is a true difference.  
 
Good patient self-performed oral hygiene is linked to clinical outcomes. 
Historically it has been reported that regular professional visits are key to 
reducing plaque accumulation (among other markers of periodontal disease) and 
by extension professionally recorded plaque scores (Lertpimonchai et al., 2017, 
Lovdal et al., 1961, Axelsson and Lindhe, 1981b). The majority of this evidence 
is available from studies examining Supportive Periodontal Therapy. For 
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example, Axelsson and Lindhe’s study in 1981 demonstrated superior plaque 
scores for patients placed on a carefully designed supportive regime, compared 
to a control group of patients not enrolled in such a program. Therefore, one 
could postulate that periodontal therapy provided over more appointments may 
yield superior plaque scores than treatment provided over a shorter 
timescale/number of appointments. In the current study, patients receiving 
hand or ultrasonic instrumentation did so over the course of two treatment 
visits, within 24 hours of each other. For comparison, subjects in the 
combination treatment arm received treatment over a minimum of four visits 
over the course of approximately two months (median number of visits = 4.5). 
Values of median (Q1, Q3) change (reduction) in plaque scores were 44.35 
(18.10, 54.58) %, 33.23 (15.21, 48.67) % and 42.0 (27.75, 56.75) % for hand 
instrumentation, ultrasonic instrumentation and combination approaches 
respectively (Figure 3-1E). These changes, between groups, were not 
statistically significant (Table 3-3). Although patients in the hand and ultrasonic 
groups had fewer treatment visits, these patients returned to the clinic for 
sample collection at day 1 and day 7 post treatment, thus resulting in a similar 
number of ‘episodes of contact’ with the professional dental team as the 
combination group – this may help explain similar plaque score changes between 
groups (assuming professional contact episodes influences changes in plaque 
score). Nonetheless, the current study suggests fewer professional treatment 
visits may be equivalent to multiple visits with regards to fortifying improved 
plaque scores for patients undergoing non-surgical periodontal treatment. 
 
Defining a reliable endpoint for ‘success’ in periodontal therapy has several 
notable challenges. The common practice of reporting mean PPD data and 
percentage of ‘closed’ pockets results in widely variable data, which is difficult 
to apply across populations with varying levels of periodontal disease. 
Consistently applying objective parameters of success, especially with such a 
complex disease as periodontitis, is undeniably challenging. Difficulties in 
reliability in measurement of PPD, BOP and plaque as well as clinical 
transferability further compound such issues. Attempts were made by a variety 
of authors (Badersten et al., 1990, Cobb, 2002), perhaps most notably Lang and 
Tonetti (Lang and Tonetti, 2003), to combine multiple indices to help achieve 
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reliable markers of success to inform further periodontal treatment decisions in 
practice. Indeed, some goals of periodontal therapy may prove to be wholly 
unrealistic (such as achieving full mouth pocket closure or BOP <10%) and 
perhaps unachievable for certain periodontal patients with more advanced 
disease. These concepts were explored in detail in a 2020 study by Feres et al 
(Feres et al., 2020). A robust attempt was made to propose a reliable single 
clinical end point for periodontal trials. This review analysed 4 RCTs with a total 
of 724 patients. Outcomes were assessed at 1 and 2 years post treatment. 
Conclusions were drawn which suggested ≤4 sites with PPD of ≥5 mm was 
‘effective in distinguishing between patients showing signs of post-treatment 
periodontal disease remission from those showing signs of uncontrolled disease’. 
Other highlighted factors of importance were BOP with >10% at 1 year being 
suggested as high risk for periodontal disease relapse. Another review article 
from 2020 (Loos and Needleman, 2020) explored clinically meaningful endpoints 
of periodontal therapy and reported the presences of PPD of ≥6 mm and 
bleeding on probing scores ≥30% as high risk for future tooth loss. This review 
included patient-reported outcomes, which are generally notable in their 
absence in the literature on periodontal treatment outcome assessment – this 
topic will be considered in Chapter 5 of the current work. In the current study, 
only 16% of study participants (10 patients) achieved Feres’ criteria of ≤4 sites 
with PPD ≥5mm. No patients fulfilled all aspects of the Scottish Dental Clinical 
Effectiveness Programme’s criteria for successful periodontal treatment 
(Scottish Dental Clinical Effectiveness Programme, 2014). The breakdown of 
constituent criteria would suggest expecting all sites to resolve to <4mm PPD is 
extremely challenging, relative to other criteria. Furthermore, findings 
presented in Table 3-4 would render 100% of patients in the current study as 
‘Currently Unstable’ in the most recent classification of periodontal disease from 
the Joint Workshop between the American Academy of Periodontology and the 
European Federation of Periodontology (Papapanou et al., 2018) as all patients 
had at least one pocket of ≥5 mm. Encouragingly, the study sample achieved 55% 
of patients reaching close to the mean level of pocket closure (57%) reported in 
a recent systematic review (Suvan et al., 2019) which reported data at 3 months 
follow up (similar to the current study).  
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Interestingly, no single patient showed consistent ‘response’ or ‘non-response’ 
with respect to their performance across an extended range of published success 
criteria in periodontology. It is worth noting that some objective criteria for 
success (SDCEP (Programme, 2014)/Lang and Tonetti (Lang and Tonetti, 2003)) 
were created to be applicable following a full non-surgical and surgical course of 
periodontal therapy (and often including a period of supportive periodontal 
therapy) and not following solely non-surgical therapy (as presented in the 
current analysis). The results presented in Table 3-4 and Figure 4 demonstrate 
published criteria of periodontal outcome assessment vary widely between each 
other and can be applied with highly variable results to real patients within the 
current clinical study. No treatment group showed superiority as judged by 
‘responder’ status (Table 3-4, Figure 3-4). However, combination 
instrumentation provided relatively high numbers of patients achieving <10% BOP 
(from SDCEP criteria), compared to other treatments. The explanation for this 
finding is not clear but may be due to more appointments to encourage oral 
hygiene and therefore reduce gingival bleeding. Nevertheless, this is contested 
by Table 3-4’s presentation of equivalence in plaque and BOP scores between 
treatment groups.  
As is evident, very low numbers of patients achieved objective clinical success as 
measured by published criteria. These results further highlight the challenges in 
predictably achieving multiple parameters of success within clinical periodontal 
therapy.  
The clinical results in the current study appear largely comparable between 
groups. However, the time taken to achieve those results was on average nearly 
22 minutes faster using ultrasonic instrumentation compared with hand 
instruments. This equates to approximately 22% reduction in treatment time if 
ultrasonic instruments exclusively were used instead of hand instruments. This 
figure is within the region of that reported in a systematic review on the subject 
by Tunkel (Tunkel et al., 2002) of 36.6%. Mean treatment time per tooth in the 
current study was 3.46 mins and 2.80 mins for hand instruments and ultrasonic 
instruments respectively, emphasising the time efficiency of ultrasonic 
instruments. This value is similar to that reported (approximately 3 
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minutes/tooth) in a seminal paper (Badersten et al., 1981). This time saving, 
coupled with the previously discussed absence of difference in treatment 
outcomes provides a compelling argument in favour of the use of exclusively 
ultrasonic instruments in the treatment of periodontitis by non-surgical means. 
The European Federation of Periodontology have also recently acknowledged the 
additional time and skill required for hand instrumentation in their 2020 S3 Level 
Clinical Practice Guideline (Sanz et al., 2020a). However, at the time of writing, 
aerosol generating procedures (such as the use of ultrasonic instruments) are 
discouraged due to potentially higher COVID-19 viral transmission risk. This 
factor may prove an important consideration in post-pandemic periodontal care. 
 
Within the context of an exploratory analysis, as disease severity increases, time 
for hand instrumentation also increases significantly. As previously shown in 
Figure 3-2, mean treatment time for ultrasonic instruments was lower overall. 
Together with the evidence of equivalent clinical outcome in the current study 
(Table 3-2, Table 3-3, Figure 3-1), these findings provide further detail of the 
efficacy of ultrasonic instrumentation (compared to hand instrumentation) 
specifically in the treatment of patients with more advanced periodontal 
disease. This theory supports the currently held belief ultrasonic instruments are 
‘less operator dependant’ (Breininger et al., 1987, Suvan et al., 2019, Newman 
et al., 2011) in comparison to hand instruments.  
 
Non-surgical treatment of periodontitis results in an initial ‘spike’ in circulating 
serum CRP levels approximately 24 hours following treatment (Graziani et al., 
2010, Graziani et al., 2015, Sanz et al., 2020b). In the current study the increase 
of Day 1 CRP was evident within RCT treatment groups (no day 1 data were 
available from the combination treatment group) (Figure 3-5). Interestingly, the 
CRP increase at Day 1 seen within the RCT data, although statistically significant 
(across all patients), was of substantially smaller magnitude compared with that  
reported in similar studies such as Graziani 2015 (Graziani et al., 2015) or 
Tonetti 2007 (Tonetti et al., 2007). Graziani et al reported a three-fold increase 
in CRP levels whereas the current study showed a mean 1.67-fold increase in 
CRP levels (across all treatment arms). As inclusion/exclusion criteria between 
these two studies are almost identical, this variation in result may be due to 
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differences in study populations, degree of trauma caused by treatment or 
sensitivity of hsCRP analysis. The mean (SD) baseline plaque score for this study 
was 52.18 (24.17) % (across all groups) whereas Graziani et al. reported 70 (26) 
% in their full-mouth debridement group. This difference may be due to patients 
in the RCT having received initial periodontal treatment with their general 
dentist. Also, study patients received a full-mouth supragingival scale prior to 
treatment (Scottish Dental Clinical Effectiveness Programme, 2014, Lang and 
Lindhe, 2015, Suvan et al., 2019) (following baseline plaque scoring), which will 
likely have reduced plaque scores even further prior to study treatments. 
Tonetti et al (Tonetti et al., 2007) reported an almost 8-fold increase in CRP Day 
1 after full mouth non-surgical periodontal treatment. It is evident that there is 
a wide range of reported CRP increase following treatment and an argument 
could be made advocating further research to clarify these findings. 
 
As post treatment CRP increase is reported to relate to periodontal treatment 
(Graziani et al., 2010) and the subsequent bacteraemia (Balejo et al., 2017), the 
influence of treatment time and its effects upon CRP level is worthy of 
consideration. Graziani et al. (Graziani et al., 2015) reported a higher CRP spike 
in their treatment group with a higher overall treatment time. It is perhaps 
logical to expect that a higher treatment time may result in a higher level of 
CRP spike following treatment. This concept was explored within the current 
analysis. Hand instrumentation was associated with a higher treatment time (vs 
ultrasonic) in the current study. At Day 1 following treatment, comparing hand 
instrumentation and ultrasonic instrumentation, absolute median change in CRP 
levels were 0.57 mg/l and 0.97 mg/l respectively, compared to baseline levels. 
No statistical significance was noted within GLM modelling in Table 3-6. When 
further additional adjustment was made for more relevant confounders, no 
statistical significance was found. Such testing may be heavily affected by both 
outlier CRP data in the RCT data set and low levels of serum CRP in the study. 
Importantly, the RCT study was powered to detect a 1.5mg/l difference in CRP 
between groups at Day 1 – a figure not manifesting in the observed Day 1 data. 
Ultimately, this finding (a difference of 0.4 mg/l) is extremely unlikely to be 
clinically significant. However, larger studies with more participants would aid in 
corroborating this finding. 
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Increase in CRP following periodontal treatment has been attributed to local 
trauma to soft tissues leading to a systemic bacteraemia (D'aiuto et al., 2004a, 
Graziani et al., 2010). It could be postulated that a more ‘traumatic’ treatment 
may lead to a higher level of systemic inflammation. Therefore, it may be 
speculated that exclusively hand instrumentation – which takes longer - may 
result in higher levels of CRP following treatment than exclusively ultrasonic 
instrumentation. Median (Q1, Q3) CRP change comparing pre (baseline) vs post 
treatment (day 90) were 0.06 (-0.56 – 0.48), 0.15 (-0.07, 1.29) and 0.08 (-0.72, 
0.41) for hand, ultrasonic and combination instrumentation respectively. These 
values are evidently very low and likely clinically insignificant. At day 90 follow 
up, CRP levels demonstrated no statistically significant differences (p = 0.28, 
95% CI -0.259 - -0.867, fully adjusted Model, Table 3-6) between the hand and 
ultrasonic treatment groups. This finding must be interpreted with caution due 
to a high number of outlier data points (as illustrated in Figure 3-5) within the 
CRP data. Furthermore, the statistical power of the current study is not 
appropriate for reliable testing of day 90 CRP data in the RCT. To put these 
figures into perspective, a similar study by D’Aiuto in 2004 (D'aiuto et al., 2004b) 
followed 94 subjects in a longitudinal cohort trial investigating systemic 
inflammation following non-surgical periodontal treatment (using mainly 
ultrasonic instrumentation). D’Aiuto et al. reported no statistically significant 
change in CRP levels two months following treatment however a significant 
decrease was noted at six-month follow up. The current study results are 
therefore in agreement with D’Aiuto’s study. An important caveat is the data 
available in the current study relates to 90 days following treatment and not a 
longer follow up. This time period may be considered post-immediate, as 
opposed to immediate. In summary, CRP change measured at 90 days following 
treatment were similar across treatment groups. 
 
A further consideration is the provision of periodontal treatment using either a 
quadrant by quadrant approach or a full mouth in 24 hours approach together 
with the effect upon CRP levels and cardiovascular disease risk. These two 
approaches were provided in the ‘combination instrumentation’ and ‘hand 
instrumentation’/’ultrasonic instrumentation’ arms respectively in the current 
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study. A 2020 joint consensus statement by the European Federation of 
Periodontology and the World Heart Foundation (Sanz et al., 2020b) stated for 
patients at risk of cardiovascular events ‘irrespective of the level of CVD… non-
surgical periodontal therapy should be provided, preferably in several 30 to 45 
min sessions, in order to minimize a spike of acute systemic inflammation’. As 
previously shown, despite the ‘post-immediate’ follow up of 90 days, no 
clinically significant differences were found between treatment delivery 
approaches (RCT groups compared to cohort group; Table 3-6) in the current 
study and therefore further research is warranted to explore this finding further. 
 
 
3.4 Summary of Key Findings 
• Periodontal treatment provided using exclusively hand instruments, 
exclusively ultrasonic instruments or a combination of these methods 
yields a comparable outcome in clinical parameters of periodontal 
disease.  
• Ultrasonic instrumentation takes less time to complete treatment than 
hand instrumentation. 
• There is a lack of consistency in parameters of a successful outcome and 
definitions of ‘responder’ status across published criteria of success in 
periodontal treatment. 
• The rise in serum CRP 24 hours following completion of full mouth 
debridement, is similar following hand or ultrasonic debridement. This 
suggests the systemic inflammatory response is similar following hand or 
ultrasonic debridement.  
• Actual serum CRP, and change in serum CRP relative to baseline, 
measured at 90 days following completion of treatment, is similar 
between all three instrumentation approaches.  
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Chapter 4: Economic Implications of Different 
Approaches to Non-Surgical Periodontal 
Treatment  
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4.1 Introduction 
Within the context of a publicly funded healthcare system such as the National 
Health Service, cost effectiveness of common treatments is an important 
consideration. Periodontal disease is known to be a highly prevalent condition, 
with a reported UK prevalence of 75% (Organization., 2005. Accessed September 
2019. Available from https://www5.dent.niigata-
u.ac.jp/~prevent/perio/contents.html) and an age-standardized global 
prevalence of 9.8% for the severe form of the disease (Bernabe et al., 2020). 
Periodontitis is therefore a very common condition, for which treatment is 
provided under the NHS. Optimising costs for such common treatments have 
potential to yield significant savings over the long term and improve ‘value for 
money’.  
 
The following cost-minimisation analysis sought to explore the cost implications 
of providing periodontal treatment by full mouth debridement using either hand 
or ultrasonic instruments (data from RCT), or by providing treatment through a 
blended approach over multiple visits (data from cohort study). The analysis 
specifically explores treatment visit organisation, periodontal instrumentation 
technique, material procurement and recurring maintenance costs. 
 
The research question ‘What are the costs of providing periodontal treatment 
within a secondary care UK dental hospital setting - comparing single modality 
treatment provided using a full mouth debridement approach (assuming 2 visits 
in 24 hours) to combination treatment provided using a quadrant by quadrant 
approach?’ is addressed herein.  
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4.2 Results 
To answer the research question of ‘What are the costs of providing periodontal 
treatment within a secondary care UK dental hospital setting - comparing single 
modality treatment provided using a full mouth debridement approach 
(assuming 2 visits in 24 hours) to combination treatment provided using a 
quadrant by quadrant approach?’, data was gathered relating to procurement, 
processing and maintenance costs of hand and ultrasonic instruments (Table 4-
1). It was assumed there was a functioning ultrasonic insert-capable dental chair 
already in situ in the dental clinic - such dental chairs have widely varying costs. 
It should also be noted portable benchtop ultrasonic units are also an option. 
Data involving clinician, nursing and decontamination staff salaries was 
unfortunately not available due to time constraints. 
 
4.2.1 Influence of Treatment Delivery Approach 
A ‘quadrant by quadrant’ approach (cohort study) was associated with a higher 
number of expenditure events, compared to a ‘full mouth in 24 hours’ approach 
(RCT data) in the current analysis (Figure 4-1) – a difference of 1.3 visits on 
average. This was due to a higher number of treatment visits in the quadrant by 
quadrant group (mean (SD) - 4.3 (1.49)) compared to the full mouth in 24 hours 
group (all patients had 3 treatment visits) (Table 4-1).  
 
 
4.2.2 Influence of Instrumentation Technique – Procurement, 
Reprocessing, Sterilisation and PPE Costs 
Comparing single instrumentation (RCT data) with combination instrumentation 
(cohort study), a higher initial expense was associated with combination 
instrumentation (Figure 4-1). The cost of procuring both hand and ultrasonic 
instruments was £724.95. This difference at the procurement stage (comparing 
ultrasonic to combination instrumentation) was calculated as £278.91 (Table 4-
1).  Furthermore, higher treatment visit number associated with combination 
 
 
 
 
108 
treatment resulted in higher sterilisation, repackaging and PPE costs for the 
combination group, compared to exclusively ultrasonic instruments – a mean 
difference of £21.64 per patient. In the case of the patient with the maximum 
number of visits in the combination treatment group (six treatment visits), 
sterilisation, repackaging and PPE costs accounted for £43.84 of expense. 
 
Exclusively hand instrumentation was associated with increased sterilisation, 
repackaging and maintenance costs when compared with using exclusively 
ultrasonic instruments. This difference equated to a further £3.52 in 
sterilisation/repackaging/PPE cost per course of treatment and a yearly 
sharpening cost of £30.40. Ultrasonic instrumentation was shown to benefit from 
minimal maintenance expenses as no sharpening was required (Table 4-1).  
 
PPE cost was the same between hand and ultrasonic instruments (Table 4-1). 
PPE cost compounded if using a quadrant by quadrant approach due to higher 
numbers of treatment visits.  
 
Overall, the treatment modality with the lowest total expense was identified as 
hand instrumentation carried out using a ‘full mouth in 24 hours’ approach 
(Table 4-1). Over an extended period, this initial low cost was offset by hand 
instrument’s higher sterilisation, repackaging and maintenance (sharpening) 
costs. The treatment with the highest expense was combination instrumentation 
performed using a quadrant by quadrant approach – a £332.38 increase, 
compared to hand instruments using a full mouth approach. High initial expense 
combined with maintenance of both hand and ultrasonic instruments led to this 
finding (Table 4-1). As shown in Chapter 3, hand instruments required less time 
for treatment (approximately 21 minutes) compared to ultrasonic instruments. 
Therefore, in the long term, the use of ultrasonic instruments, rather than hand 
instruments, may result in more efficient use of the dental surgery.  
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Figure 4-1 – Schematic of Costs Associated with Periodontal Treatment  
 
Schematic of associated expense events associated with periodontal treatment within 
the protocols of current study interventions. 
 
Please refer to Table 4-1 for itemised cost details 
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Table 4-1 – Itemised Costs of Periodontal Instrumentation Techniques  
Table of itemised costs in Pound Sterling (£) for each stage of the purchase, 
sterilisation and maintenance of periodontal instruments within current study 
protocols. 
 
Data were gathered through liaison with NHS Procurement staff and Central Sterile 
Services Department managerial staff based at Glasgow Dental Hospital. 
 
PPE cost data from https://www.dental-directory.co.uk/news/ppe-predicted-price-
uplifts-post-lockdown/(accessed July 2020).  This data does not account for COVID-era 
FFP3 masks and enhanced PPE currently used during aerosol generating procedures. 
 
*mean number of treatment visits (including baseline supragingival ultrasonic scaling 
visit) 
§all inserts and barrel 
†cost per full course of treatment (assuming 4 visits for combination instrumentation 
and 3 visits for single modality instrumentation) 
Instrumentation 
Technique 
(Delivery 
Approach) 
Procurement 
Sterilisation 
and 
Repackaging† 
Maintenance 
(yearly) 
PPE 
cost 
(per 
visit) 
Visits* 
Total 
Expense 
 
Single (Ultrasonic) 
Instrumentation 
(full mouth in 24 
hours) 
 
£446.04 § 
 
 
£8.76 
 
 
£0 
(2-minute wear 
check on clinic) 
 
£0.33 3 £455.79 
 
Single (Hand) 
Instrumentation 
(full mouth in 24 
hours) 
 
£278.89 
 
£12.28 
 
 
£30.40 
(sharpening) 
£0.33 3 £322.05 
 
Combination 
Instrumentation 
(quadrant by 
quadrant) 
 
£724.95 £30.40 
 
£30.40 
(sharpening of 
hand 
instruments) 
 
£0.33 4.3 £788.17 
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4.3 Discussion 
Data presented in this chapter identifies combination treatment using a 
quadrant by quadrant approach as the most expensive periodontal intervention 
studied. The overall least costly intervention, in the short term, was hand 
instrumentation using a full mouth in 24 hours approach – not accounting for 
time taken for treatment. 
 
At the time of writing, operator PPE is a pertinent consideration, in the context 
of the current COVID-19 pandemic. A higher frequency of donning and doffing 
events is associated with treatment provided using a quadrant by quadrant 
approach due to a higher number of treatment visits. With the use of enhanced 
PPE (Cochrane, 2020) to limit transmission of the virus, higher costs are 
inevitable if this practice is maintained in the future. Costs could therefore be 
minimised by performing fewer donning/doffing procedures associated with a 
full mouth treatment approach. From Figure 4-1, it is evident a single 
instrumentation approach delivered via a full mouth in 24 hours technique has 
the least associated cost with least events of expenditure. 
 
Exclusively hand instruments (full mouth treatment in 24 hours) may be 
significantly less costly at procurement, when compared to ultrasonic 
instruments (Table 4-1). However, as time passes, ultrasonic instrumentation has 
less maintenance requirements (no sharpening required), lower sterilisation 
costs and processing costs. The use of ultrasonic instruments eliminates the 
yearly £30.40 sharpening fee incurred by treatment involving hand 
instrumentation. This yearly figure is an estimate and many manufacturers 
recommend sharpening hand instruments following each use. Moreover, the 
lower sterilisation and processing cost of ultrasonic instruments yielded a £3.52 
cost saving per full course of non-surgical periodontal treatment. This is due to 
the higher number of physical instruments in a hand instrument kit (eight hand 
instruments compared to five ultrasonic inserts per kit in the current study) – 
resulting in higher sterilisation and reprocessing expense. Currently, the COVID-
19 pandemic highlights that ultrasonic use is an aerosol generating procedure 
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(AGP) and therefore requires additional PPE and fallow time between 
procedures. At this time, therefore, the data presented here could be used as a 
basis for cost calculations of time savings vs PPE/fallow time costs. There are 
likely to be ongoing changes to AGP risk mitigation strategies. For example, it 
could be speculated that accurate point of care testing and eventually successful 
vaccination and herd immunity are possible. Such changes would negate the 
need for additional PPE and fallow times for AGPs, and thus the current findings 
would again be applicable.  No data exists on instrument longevity for ultrasonic 
instruments due to numerous variables involved – for example: tip wear, insert 
stack deformation, barrel coil malfunction and irrigation malfunction. 
Combination instrumentation treatment on a quadrant by quadrant basis was 
more expensive than either single instrumentation approach. This is explained 
by: the purchase of both instrument sets initially; more visits for treatment; 
more PPE expenses; both instrument sets requiring sterilisation and repackaging 
at each visit and also sharpening needed for hand instruments.  
 
Aside from the cost to the NHS (Table 4-1), patient appointments also have an 
associated cost for the patient themselves. This cost includes lost earnings, 
expense of travelling to the clinic and time spent in the appointment (it is 
assumed the patient is travelling from and to their place of residence). Using UK 
based data (including treatment time data from the current study) this cost may 
be estimated at approximately £20.85 per appointment (calculated using 
average hourly UK income (£11.82 (Gov.Uk, 2020)), average distance from a UK 
dental surgery [mean 10.7km (England, 2018)], average public transport [UK 
return bus ticket- £2.33 (Tas, 2018)] costs and approximate bus speed 
[60km/hr]). Therefore, it is advantageous that treatment is provided over fewer 
appointments if possible. Not only would this practice save NHS money (Figure 4-
1, Table 4-1) but patient expenses are also minimised.  
 
Costings discussed within this chapter were gained from a local NHS material 
acquisition portal and thus may vary significantly according to health board and 
general dental practice. This may adversely affect the external validity of the 
findings. Monetary values presented serve as an indication of potential costings, 
not an absolute representation. No consideration was given to the purchase cost 
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of an ultrasonic base unit itself – these units are associated with significant cost 
implications and would potentially affect results further in favour of hand 
instruments. This factor was discounted as ultrasonic base units were readily 
available within the NHS Dental Hospital environment studied. Such dental chairs 
can cost in the region of £2499.99 (DentalPlaza®) to £3562.55 (Quirumed®) and 
beyond. Benchtop ‘portable’ ultrasonic machines have a cost of approximately 
£400 but may reach costs of up to £1600 (Cavitron® Jet Plus), subject to 
manufacturer and features. With regard to time efficiency of treatment and its 
associated costs, a UK based private dental hygienist hourly rate has been 
reported between £27/hour and £32/hour (based on data from 1,216 salaries 
(Neuvoo.Co.Uk, 2020)). It is therefore not an insignificant saving for an employer 
to recommend the use of exclusively ultrasonic instruments – given this study’s 
findings of faster treatment and similar clinical outcomes (Chapter 3). In the UK 
NHS general dental practice setting, the ‘break even’ hourly rate for NHS 
dentistry has been reported as £93/hour (Council, 2003). The utilisation of ‘full 
mouth in 24 hours’ treatment and single modality treatment therefore would 
improve practitioner’s likelihood of achieving this challenging target. 
 
Challenges exist in applying standard economic health measures to dentistry 
and, in particular, periodontology. A measure such as the Disability Adjusted Life 
Year (DALY) was created by the World Health Organisation, accounts for 
mortality and nonfatal health consequences and is often used as a denominator 
in cost-effectiveness ratios (Salomon, 2014) for healthcare interventions. 
However, its application to periodontology is challenging as the ‘disability’ 
caused by periodontal disease often manifests as compromises in stress levels 
(Marcenes and Sheiham, 1992) and quality of life (Ferreira et al., 2017, 
Needleman et al., 2004) for the patient which are notoriously difficult to 
quantify in monetary terms. Emerging evidence of a correlation between 
improvements in quality of life and patient’s willingness to pay for an 
intervention (Lachaine et al., 2003) may yield promise in quantifying 
improvements in QoL in monetary terms. However, there exists a need for 
further research into this field to aid future periodontal intervention economic 
analyses. 
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4.4 Summary of Key Findings 
• Periodontal treatment provided using a single instrumentation approach is 
less costly than using a combined instrumentation approach. 
• Periodontal treatment delivered by a ‘full mouth in 24 hours’ approach 
was associated with fewer episodes of expenditure, compared to a 
‘quadrant by quadrant’ approach. 
• Ultrasonic instrumentation was associated with the highest initial 
procurement cost however had the lowest maintenance and processing 
costs, and was associated with faster treatment time, which may further 
offset higher initial purchase costs. 
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Chapter 5: Patient Perspectives of Periodontal 
Treatment “Study 1” 
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5.1 Introduction 
Quality in healthcare is multifaceted, described as involving multiple concepts 
including ‘effectiveness’, ‘efficiency’, ‘equitable’, ‘safety’, ‘timeliness’ and 
‘patient-centredness’. Furthermore, driving up quality, is one of the core values 
of the ‘Mission Statement’ for NHS Scotland (Communications, 2020). Within the 
last 10 years, particular emphasis has been placed on patient reported outcomes 
as a measure to assess quality in healthcare (Baiju et al., 2017). Furthermore, a 
patient centred approach comprises treatments regarded as valuable and 
effective by patients themselves. The benefits of periodontal treatment from a 
clinical perspective have been explored both within this study and in the wider 
literature (Suvan et al., 2019). However, reports of patient experience 
specifically following periodontal therapy are an area requiring further research 
and indeed may be key in the development of meaningful endpoints of 
periodontal treatment (Loos and Needleman, 2020). 
 
This chapter aims to capture and discuss patient reported outcomes associated 
with different periodontal instrumentation techniques and address the research 
question ‘What were patient experiences of receiving periodontal treatment?’.  
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5.2 Results 
5.2.1 Patient Reported Outcomes – Frequencies 
Patient reported outcomes were analysed within the RCT Study only. Patients 
(“Study 1”) in both RCT treatment groups found treatment effective, of 
educational value and had many positive comments, particularly relating to 
clinical staff (Table 5-1). Comments relating to positive results from treatment 
started to emerge from Day 7 and were most common at Day 90 in both groups. 
Two patients commented on the benefits of undergoing all treatment in a single 
day (Table 5-1).  
 
High numbers of comments reporting ‘no/nothing’ (Table 5-2) when asked to 
suggest improvements to the treatment were documented. This implies, 
although does not confirm, patient satisfaction with study interventions. Of a 
potential 38 patients, 30 patients commented at day 90 they had no suggestions 
for improvements – the most frequent comment in the current analysis. 
 
Issues raised included those unrelated to study interventions such as parking and 
travel (6 comments across all timepoints, both groups). The addition of a 
distraction in the form of background music was noted, particularly for the hand 
instrumentation group (6 comments across all time points) (Table 5-2, Figure 5-
3). A single comment of ‘grinding noise of scaler’ was submitted in the hand 
instrument group at day 90. There were no such comments along the theme of 
noise in the ultrasonic group at any time point (Table 5-2).  
 
Responses were collected at day 1, day 7 and day 90. Patient responses were 
broken down into themes, timepoints collated and only individual patient’s 
overall comment counted, thus excluding repeated duplicate responses by the 
same patient. These data demonstrated approximately equal numbers of 
patients in both treatment groups commenting on the positive experiences from 
treatment and also positive results from treatment. For example, seven patients 
(37%) in the hand instrumentation group commented on positive experiences of 
 
 
 
 
118 
treatment; where eight patients (44%) in the ultrasonic instrumentation group 
provided such comments. Patients in both groups had similar concerns over 
accessibility of the dental clinic (Table 5-3). No patients in the ultrasonic 
instrumentation group communicated issues with the noise generated during 
treatment; whereas three unique patients reported this issue in the hand 
instrumentation group (Table 5-3). Difficulties accessing the clinic were reported 
by both hand instrumentation and ultrasonic instrumentation treatment groups 
at two and three patients respectively.  
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Table 5-1 - Patient reported outcomes following periodontal treatment – 
Question 1 
Frequency table of patient reported outcomes to a question asked to patients following 
treatment using hand or ultrasonic instruments: ‘Thinking about the treatment in your 
own words, can you describe the experience of treatment?’ Responses were analysed 
and categorised into themes and tabulated. 
Please note no data was available for combination treatment and some comments are 
repeated by the same patient across time points.  
Hand Instrumentation 
(n=19) 
Ultrasonic Instrumentation 
(n=18) 
Day 1 Day 7 Day 90 Day 1 Day 7 Day 90 
‘Amazing’ 1 - 4 1 1 1 
‘Pain Free’ 6 3 - 3 1 3 
‘Comfortable’ 1 - - 3 - - 
‘Friendly/caring 
Staff’ 
1 3 1 3 - 7 
‘Positive experience’ 3 - 1 1 2 - 
‘Well informed’ 2 1 - 1 1 - 
‘Educational’ 3 3 10 2 3 1 
‘Straightforward’ 2 - - 1 - - 
‘Thorough’ 1 1 3 2 2 - 
‘Very pleasant’ 1 1 - - - - 
‘Professional’ 1 2 2 3 - - 
‘Put at ease’ 1 1 3 - 1 - 
‘Good’ - 1 - 1 4 2 
‘Fantastic’ 3 3 1 2 1 1 
‘Relaxing’ 1 - - 3 2 1 
‘Better than 
expected’ 
2 - - 3 - - 
‘Happy treatment 
completed in one 
day’ 
- 2 - - - - 
‘See the difference’ - 1 2 - 3 - 
‘No bleeding’ - 2 3 - - - 
‘Great result - - 5 - - 6 
‘Mouth feels cleaner’ - - 3 - - 2 
‘No sore gums’ - - 2 - - - 
‘Improved 
confidence’ 
2 - - - - 2 
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Table 5-2 – Patient reported outcomes following periodontal treatment – 
Question 2 
Frequency table of patient reported outcomes to a question asked to patients following 
treatment using hand or ultrasonic instruments: ‘Is there anything that would have 
made it a better experience?’  
Responses were analysed and categorised into higher level themes and tabulated. 
Please note no data was available for combination treatment and some comments are 
repeated by the same patient across time points. 
 
  
 
 
 
Hand Instrumentation 
(n=19) 
Ultrasonic Instrumentation 
(n=18) 
Day 1 Day 7 Day 90 Day 1 Day 7 Day 90 
‘No/Nothing’ 13 13 14 15 11 16 
‘Don’t think so’ 1 1 - 1 - - 
‘Difficult to access 
clinic’ 
1 1 - 1 - - 
‘Honestly no’ 1 - - - - - 
‘Difficulty parking’ - - - - 2 - 
‘Not sure’ - - - - 2 - 
‘Travel’ 1 1 2 - - - 
‘Addition of 
background music’ 
2 2 2 - - 2 
‘Appointment 
reminders’ 
- - - - - 1 
‘Cup of tea’  - 2 - - - - 
‘Grinding noise of 
scaler’ 
- - 1 - - - 
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Table 5-3 – Patient responses to Question 1 and Question 2 – High Level 
Themes 
Frequency table of patient reported outcomes to questions asked to patients following 
treatment using hand or ultrasonic instruments.  
Unique patients responding within themes are shown, across all time points combined.  
Some patients are counted across multiple comments. 
 
 
  
 
Theme of Comment 
 
Hand Instrumentation 
(n=19) 
Ultrasonic 
Instrumentation 
(n=18) 
Positive Experience of 
Treatment 
7 (37%) 8 (44%) 
Positive Results of 
Treatment 
5 (26%) 6 (33%) 
Clinic Accessibility 
Difficulties 
2 (11%) 3 (17%) 
Noise of Treatment 3 (16%) 0 
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5.2.2 Patient Reported Outcomes – Visualisation of patient 
response 
Appreciation of trends in data was gained by the creation of word clouds, a 
content analytic technique based on frequency of occurrence. Word clouds were 
utilised due to their simplicity in communicating the focus of a group of 
qualitative, free-text data (Atenstaedt, 2012). This technique has been 
demonstrated to improve comprehensibility of data, particularly for individuals 
not familiar with numerical tables or statistical analysis methods (Bletzer, 2015). 
 
Overall, comments had very similar themes between groups. Common themes 
included pain free treatment, thorough treatment, praising of staff manner and 
satisfaction at results from treatment (Figure 5-1, Figure 5-2). These themes 
were alike, often with the same vocabulary, across treatment groups. 
 
Similarly, responses to the question asking for suggestions for improvements to 
study protocols were comparable between treatment groups, with the trend 
emerging of more numerous comments regarding noise generated during 
treatment within the hand instrumentation group. Some patients in the hand 
instrument group also mentioned the desire for a cup of tea – although this 
seemed to relate to recovery after providing blood samples akin to what happens 
in the blood transfusion service. Again, satisfaction with treatment was inferred 
through numerous ‘no’ responses to this question. Word clouds (Bletzer, 2015) of 
positive comments are densely populated (Figure 5-1). In comparison, the word 
clouds on potential improvements having excess empty space highlights patients’ 
apparent satisfaction with study interventions (Figure 5-2).  
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Figure 5-1 – Word clouds of patient reported outcomes to Question 1 
Word cloud of common responses to the question posed after treatment: 
‘Thinking about the treatment in your own words, can you describe the experience of 
treatment?’ 
 
Responses were analysed and categorised into themes. 
 
Day 1, Day 7 and Day 90 responses were pooled, and separate word clouds created for 
hand instrumentation and ultrasonic instrumentation groups. 
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Figure 5-2 – Word clouds of patient reported outcomes to Question 2 
 
Word cloud of common responses to the question posed after treatment: 
‘Is there anything that would have made it a better experience?’ 
Responses were analysed and categorised into themes. 
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5.3 Discussion 
Data in the current chapter explored patient-centred reported outcomes 
following periodontal treatment by one of two instrumentation techniques. Key 
findings included high levels of patient satisfaction and comments relating to 
positive results from treatment.  
As with all healthcare, modern periodontal treatment should strive to be as 
patient centred as possible. A systemic review (Buset et al., 2016), following 
assessment of 37 eligible studies, found evidence of an association between 
periodontal disease and negative effects upon oral health related quality of life 
(OHRQoL (Sischo, 2011))– a form of patient reported outcome. OHRQoL is a 
multidimensional framework used to aid assessment of the impact oral 
conditions and treatments have upon various facets of a patient’s quality of life. 
Examples of fields included are: ‘function’, ‘satisfaction’, ‘pain’ and ‘bleeding 
gums’. Information pertaining to such fields were captured within the current 
study data set (Table 5-1, Table 5-2). However, data was unable to be translated 
directly into an OHRQoL score due to limitations in free-text, open questioning 
in the RCT study. Across both treatment groups following the provision of 
periodontal care, seven comments related to comments regarding ‘function’; 
twenty-two comments noted ‘satisfaction’; sixteen comments related to ‘pain’ 
and five comments explicitly mentioned ‘bleeding gums’ (Table 5-1). It would 
therefore appear that patients in this study, without being confined to the 
leading questions involved in formal assessment of OHRQoL, still offer responses 
similar to those included in the OHRQoL assessment proper. The OHRQoL has 
already been validated for clinical use and endorsed by the World Health 
Organisation (Petersen, 2003). However, these findings may lend further 
evidence to its application within clinical periodontal treatment. A promising 
iteration of the OHRQoL may lie in the OHIP-CP tool, developed in 2017 (He et 
al., 2017) with a specific focus on chronic periodontitis. Validation of this tool 
appears very promising, with a reported Cronbach’s alpha of >0.7. However, its 
application in further studies is warranted to elicit repeated reliability in the 
clinical setting. 
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Assessment of patient outcomes in the RCT was a secondary outcome. Each 
question posed to patients had a subtly different focus. The first question 
‘Thinking about the treatment in your own words, can you describe the 
experience of treatment?’ may be regarded as a question probing patient 
experience. On the other hand, the second question ‘Is there anything that 
would have made it a better experience’ refers to both the experience of 
treatment received and also encourages suggestions for improving the service 
provided overall. As patients were already donating extra time to provide study 
samples (whole blood, saliva, GCF, plaque) it was felt inappropriate to impose 
further time burden by the addition of a fully validated questionnaire. This 
parsimonious technique was felt to be the most appropriate in the context of the 
study. Questions were discussed with a behavioural psychologist prior to their 
use in the study. However, a 2015 review, considering nine questionnaires from 
a variety of medical settings, suggested an inverse relationship between the 
length of a patient feedback questionnaire and the accuracy of patient 
responses (Pierce et al., 2015). It was accepted the results from the current 
open questions would not be of the same quality as those from a validated, more 
detailed, questionnaire. Results gained from the current study may serve to aid 
future studies in development of a novel periodontal outcome specific 
questionnaire. 
 
A systematic review emphasised the importance of considering patient reported 
outcomes in the assessment of periodontal care (Baiju et al., 2017). This study 
analysed 19 clinical studies and 2 other systematic reviews, reaching the 
conclusion both surgical and non-surgical periodontal treatment have significant 
beneficial effects upon oral health related quality of life. Furthermore, a recent 
publication from the European Federation of Periodontology (Loos and 
Needleman, 2020) recommends a greater emphasis being placed on patient 
reported outcomes in periodontal treatment moving forward. Special mention of 
‘tangible’ outcomes such as ‘no pain’ and ‘aesthetic appearance’ are presented. 
Again, in the current analysis, patients often commented on such factors via 
open ended questioning following treatment (Table 5-1, Figure 5-1).  
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Overall, patients in this study reported satisfaction following periodontal 
therapy – whether provided by exclusively hand instrumentation or exclusively 
ultrasonic instrumentation. This is evidenced by the high numbers of comments 
such as ‘fantastic’, ‘positive experience’ and ‘amazing’. Interestingly, a high 
proportion of patients reported treatment as an ‘educational’ and ‘informative’ 
experience, particularly at Day 90 in the hand instrumentation group (Table 5-
1). Information provided to patients between groups was consistent, however. 
This finding may be a reflection of the lack of opportunities for patient 
education within general practice NHS dentistry in the UK - one of the key 
findings of a 2019 survey of UK based NHS dentists (Plan, 2019). 
 
Another trend in patient feedback was, as time went on, the positive visual 
results from treatment (Table 5-1, Figure 5-1). Across all patients, six comments 
relating to this theme emerged at Day 7. However, by Day 90, twenty-one 
comments made reference to noticing improvements in either appearance or 
sensation of the gingivae. This finding is in line with expected timelines of 
resolution of clinical signs of inflammation (Lang and Lindhe, 2015) and serves as 
an interesting confirmation of this pre-existing evidence.  
 
As previously described, there were minimal differences in emergent themes of 
comments in patient comments, comparing hand instrumentation and ultrasonic 
instrumentation groups. Overall, patients were satisfied with treatment and 
often could not suggest any improvements (Table 5-2, Table 5-3). It must be 
noted however patients may feel they are not best placed to comment on how 
to improve a complex service such as periodontal care in a secondary care 
setting and responses may be tempered due to this. Suggestions for 
improvements to treatment (relevant to study interventions) commonly included 
a desire for the addition of background music – likely as a distraction technique. 
This was found in both groups however was more common in the hand 
instrumentation group (Table 5-2, Table 5-3, Figure 5-2). A single comment in 
the hand instrumentation group explicitly references the ‘grinding noise of 
scaler’. As displayed in Table 5-3, three separate patients made comment upon 
the unpleasant noise of treatment in the hand instrumentation group. This 
finding was not seen in the ultrasonic treatment group. Overall, the data would 
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suggest patients are more disturbed by the operative noise produced by hand 
instruments, compared to ultrasonic instruments. The reliability of this finding is 
improved given its reporting by multiple patients (Table 5-3). Ideally, such 
findings would be evaluated by a split mouth or cross over study using each 
instrumentation technique in turn. 
 
In recent years, patient access to dental care has emerged as a contemporary 
issue in both UK based (Freeman, 1999) and American populations (Bertolami, 
2011). Developments have been focused on improving access to dental care in 
the primary care setting – as this is where the majority of treatment 
(particularly periodontal care) is provided. However, access to NHS specialist 
level care was identified by the Royal College of Surgeons England in their 2015 
‘Actions for the Government to Improve Oral Health’ document (England, 2015). 
Common barriers to accessing dental care include dental anxiety, cost of 
treatment, perception of need and lack of access (Freeman, 1999) – which may 
manifest as communication difficulties or physical inability to access the clinic. 
In the current study, nine comments referred to access issues (Table 5-2). These 
comments were offered by five patients (Table 5-3). Furthermore, five 
comments alluded to dental anxiety (Table 5-2). Two comments also 
communicated appreciation at treatment being completed within a single day – 
another indication access and convenience are important issues for patients. It 
should be noted illustration of these results (Table 5-2, Table 5-3, Figure 5-1, 
Figure 5-2) allows assessment of the number of times these issues are raised 
however provides no data on the intensity of these feelings. These findings are 
confirmatory that patients do indeed report concerns relating to access in the 
context of clinical periodontal care. Further research in this field is therefore 
warranted to alleviate such issues and optimise future service development – 
specifically within a wider population, rather than the bespoke population 
studied in the current analysis. Future studies could utilise more focused 
questioning such as ‘name one thing that would improve the service you 
received’ – a technique which may have increased the number of responses to 
Question 2 in the current study and enhanced results.  
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The brevity of the questionnaire may be regarded as a strength of the current 
analysis as patients were not overburdened with data collection techniques and 
themes were able to be readily analysed. Weaknesses of the patient-reported 
outcome data include lack of in-depth questioning and in responses from the 
same patient being counted across multiple time points. However, Table 5-3 
presents data with elimination of repeated responses across the same patient at 
different time points in an attempt to minimise this issue. 
 
As discussed in Chapter 3, significant challenges remain in assessing outcomes 
within periodontology - challenges such as: variable reliability of success criteria 
across individual patients/populations and difficulties in combining multiple 
clinical variables into a single outcome measure. The inclusion of validated 
patient reported outcomes within a robust model (which also includes a variety 
of clinically meaningful outcomes) could serve to improve our ability to assess 
success following periodontal treatment for our patients in a balanced way. 
Further study into combining the fields of patient reported outcomes and clinical 
periodontal outcomes in periodontal care - specifically validation of meaningful 
changes in such outcomes - would prove valuable. Recent developments in this 
area of determination of the minimal important difference in quality of life 
measures specific to chronic periodontitis may prove valuable in quantifying the 
holistic benefits of periodontitis treatment in future research (He et al., 2020). 
The DAS28 scoring system (Leeb et al., 2004), for rheumatoid arthritis, is an 
effective example of a holistic model in healthcare which may serve as 
inspiration for a similar system within periodontology. This system combines 
objectively swollen joint counts, patient reported outcomes, blood markers and 
patient discomfort to arrive at an overall score – which has proven valuable as an 
amalgamation of the aforementioned variables.  
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5.4 Summary of Key Findings 
• Patients were satisfied with the experience and outcome of both hand 
instrumentation and ultrasonic instrumentation. 
• Patients in both treatment groups commented on notable improvements 
in self-perceived oral health. 
• The only theme emerging of a negative experience relating to treatment 
was unpleasant noise. This finding occurred only in the hand 
instrumentation group. 
• Some patients in both treatment groups commented on difficulties 
accessing the dental hospital clinic. 
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Chapter 6: General Discussion and Conclusions 
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6.1 Discussion 
This thesis, and associated publication (Johnston et al., 2020) document the first 
randomized controlled trial to investigate the impact of different periodontal 
instrumentation techniques on systemic inflammation following full-mouth 
debridement. As expected, a significant increase in CRP was observed one day 
following treatment across all patients; however, the increase in CRP at day 1 
did not differ following hand or ultrasonic instrumentation.  The data presented 
here demonstrate similar clinical outcomes following periodontal 
instrumentation, regardless of instrumentation technique. Differences in 
systemic inflammation, measured at 90 days post operatively showed no clinical 
significance. The exploratory cost/time analysis suggests in a specialist hospital 
setting, full mouth debridement, using exclusively ultrasonic instruments results 
in a cost and time saving compared with hand or combined instrumentation. 
Therefore, these findings have potential to impact on delivery of specialist 
periodontal care in the hospital setting. 
 
The process of combining a data set from a cohort study with a randomised 
controlled trial, allowed a third comparator arm (combination treatment) to 
become available for analysis. The technique of using a combination of hand and 
ultrasonic instruments as a standard practice in the context of non-surgical 
periodontal therapy is well reported throughout the literature (Krishna and De 
Stefano, 2016, Suvan, 2005, Suvan et al., 2019, Cobb, 1996). The inclusion of a 
comparator arm was employed as a means of allowing the comparison of single 
modality treatment with a ‘treatment as usual’ arm using a combination 
approach. This technique has potential benefits of improving external validity 
and clinical application of the current study’s findings. Each included study’s 
design has its own advantages and disadvantages. Firstly,  cohort studies in 
general are able to ‘identify and evaluate cause or risk factors of diseases or 
health-related events’ (Song and Chung, 2010) by monitoring the disease status 
in a group of subjects prior to and following an intervention. Benefits of cohort 
studies include: effective design to study rare exposures/diseases, assessment of 
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multiple outcomes possible and provide information of temporal relationships. In 
the example of the current analysis, the cohort study provided temporal data 
follow up following periodontal instrumentation using a combination approach. 
In a wider periodontology context, such a study design provides the potential to 
collect valuable temporal data of a variety of variables such as disease 
resolution, systemic inflammatory state and subgingival microbiome diversity. 
This data allows key analyses of changes over time. Cohort studies are not 
without disadvantages and may have less stringent inclusion/exclusion criteria 
compared to a randomised controlled trial; may be challenging in the context of 
rare diseases; have more opportunities for bias and are potentially subject to 
costly follow up regimes. The current cohort study however was generally well 
designed and only a subsection of patients treated were used in the current 
study – so as to reduce heterogeneity in the data set.  
 
As discussed in Chapter 2, the other study included in the current analysis was a 
randomised controlled trial (IRAPT). Randomised controlled trials are integral to 
evidence based dentistry and crucially aid in the development of causal 
relationships (Collins and Macmahon, 2001). In the IRAPT study, aspects of 
design were incorporated to avoid common pitfalls (biases). Firstly, a clinically 
relevant research question was developed, in the PICO (patient, intervention, 
control/comparison, outcome) format – this is described in Chapter 2, Section 
2.1. The appropriate sample size was determined by effect size estimates from a 
pilot study (Chapter 2, Section 2.1.5)). The sample size was designed to be 
appropriately large to avoid making a Type 1 error – a false positive result. 
Inclusion and exclusion criteria were predetermined to reduce potential effects 
of confounding variables (a topic explored in Chapter 3, Section 3.2.3) and 
subjects were as similar to one another as possible to maximise the concept of 
baseline matching. Subjects were then randomised to interventions via 
concealed allocation (in the case of IRAPT – opaque envelopes) – a technique to 
minimise selection bias and ensure confounders were as equally distributed as 
possible to each treatment group. Ideally, subjects, operators and study 
statisticians should be blinded throughout the course of the study – to minimise 
performance bias caused by differentials in investigational intervention or of 
exposure factors that are not related to the intervention (Schulz and Grimes, 
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2002). This was employed as far as possible in IRAPT however the operator was 
unblinded when providing treatment. The current combined analysis sought to 
uphold the benefits of RCT randomisation by comparing hand and ultrasonic, and 
then included a 3-group comparison analysis that included comparison with the 
blended approach.  An ‘ideal’ trial design for comparing clinical efficacy of 
different instrumentation regimens is detailed below.  
 
With regards to clinical and systemic inflammatory outcomes, the current study 
(being a post hoc analysis) was not specifically powered to demonstrate either 
equivalence, a difference or superiority between treatment groups. It should be 
noted the intention of this analysis was not to provide a robust analysis of 
clinical nor systemic inflammatory outcomes.  With this in mind, the results of 
presented statistical analyses must be interpreted with extreme caution. 
However, useful data has been produced in the context of studying clinical 
outcomes of periodontal disease, specifically within a UK based urban 
population. The current analysis could be viewed as a pilot study, as it is a 
scaled down version of a potential subsequent study and successfully 
demonstrated feasibility of such a study. However, this work is ultimately a post-
hoc analysis.  The current analysis yielded multiple fields of data of value in 
future research, as will be discussed in this chapter. Data relating to effect size 
in changes of clinical variables that may be expected following non-surgical 
periodontal treatment has been gained by the current work. Put into context of 
discussions presented in ‘Clinical Success in Periodontal Treatment’ within 
Chapter 3, a clinically meaningful effect size may be estimated for use in sample 
size calculations in future research investigating the effects of periodontal 
treatment. Regarding designing such a study on the clinical effects of 
periodontal treatment, PISA has been chosen as the most appropriate single 
clinical outcome measurement as it provides a convenient single measure of 
disease state and an indication of the inflammatory status of the periodontal 
tissues – this may also be relevant for potential future studies investigating 
systemic inflammation following periodontal disease. An estimated power 
calculation for a hypothetical future study inspired by the work of the current 
study is presented in Table 6-1. As is evident, a larger sample size would be 
required to demonstrate equivalence of treatment groups in light of data 
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provided by the current study (expected effect size from treatments, mean data 
and standard deviation data). A similar estimation may be carried out for the 
measurement systemic inflammation changes following periodontal treatment 
(CRP level). Establishment of a clinical meaningful change in CRP level (including 
effects on ‘hard outcomes’ such as ischaemic events) following treatment 
remains largely unanswered (Graziani et al., 2015, Graziani et al., 2019, Bansal 
et al., 2014) despite movements to alter clinical practice by a joint statement 
by the European Federation of Periodontology and the European Heart 
Foundation (Sanz et al., 2020b), as discussed in Chapter 3. Therefore, the 
current study’s results may have direct application in performing a priori power 
calculations in future studies aimed at investigating such a popular topic in 
contemporary periodontology.  
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Table 6-1 – Future Ideal Study Design 
Ideal future study design to assess clinical outcome equivalence between periodontal 
instrumentation techniques, using data produced by the current study. An estimate of 
required sample size with results of an approximate power calculation (Julious, 2004) 
is presented. 
 
*Observed differences in PISA between treatment groups in the current study were 
regarded as clinically insignificant 
 
§Difference between means of treatment groups acceptable for ‘equivalence’ set at 
400mm2. Patient numbers not including potential for drop out. 
 
Research Question: For patients receiving periodontal treatment, are clinical 
outcomes achieved by non-surgical treatment using hand instruments, ultrasonic 
instruments or combination instruments equivalent? 
Primary outcome 
measure 
Differences in change in PISA following treatment  
(measured at 90 days following treatment) 
Study Design 
3 arm randomised controlled, parallel group, equivalence 
trial 
Power and 
Significance levels 
Alpha = 0.05 
Beta = 0.2 
Power = 0.80 
Observed measure of 
effect size  
(Change in PISA) 
from current study; 
median (Q1,Q3)* 
Hand 
936.10  
(304.36, 1392.59) mm2 
Ultrasonic 
743.57  
(268.76, 1589.81) mm2 
Combination 
1167.35  
(674.53, 1743.58) mm2 
Mean and Standard 
Deviation of Change 
in PISA from current 
study 
1057 (708) mm2 
Approximate 
minimum sample size 
required for each 
group in proposed 
RCT§ 
54 patients per group (162 total) 
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The data presented throughout this thesis suggest clinical outcome 
comparability between all instrumentation techniques. Chapter 4 explored the 
financial implications to both the NHS and the patient with regards to delivering 
periodontal treatment through a cost minimisation analysis. The use of a ‘full 
mouth in 24 hours’ approach using a single modality (either hand or ultrasonic 
instrumentation) showed interesting benefits in cost effectiveness and potential 
for minimising number of treatment visits (Figure 4-1, Table 4-1). Chapter 5 then 
presented patient perspectives of periodontal therapy. It was demonstrated 
patients were largely satisfied with results achieved from both instrumentation 
techniques studied (Table 5-1). Furthermore, only patients in the hand 
instrumentation group reported negative comments relating to the noise of 
treatment (Table 5-3), an interesting finding. This was surprising as it was 
assumed patients may preferentially comment on the ultrasonic creating an 
unpleasant noise, as opposed to hand instruments – this topic would benefit from 
more focused research. In summary, the current analysis would suggest ‘full 
mouth in 24 hours’ treatment provided using exclusively ultrasonic 
instrumentation has notable benefits in reduced time for treatment, less 
reprocessing/sterilisation costs and similar clinical and systemic inflammatory 
results - compared to other instrumentation and treatment delivery approaches 
studied. 
 
Some notable limitations exist within the current study. Patients included were 
chosen from two separate studies conducted in isolation. All patients were keen 
to take part in research – this may result in artificial selection of compliant 
patients and thus inflate study results. Results therefore may lose an element of 
validity for less compliant patients and a wider population. It could therefore be 
argued that results from the current study are more clinical efficacy data than 
clinical effectiveness data - clinical efficacy being defined as ‘the impact of 
interventions under optimal ‘trial’ conditions’ and clinical effectiveness defined 
as ‘whether interventions have the intended or expected effect under ordinary 
(clinical) circumstances’(Gosall, 2015). Combining results from studies is also not 
ideal however attempts were made to homogenise the data set such as baseline 
matching by inclusion/exclusion criteria, as guided by the randomised clinical 
trial protocol. 
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By virtue of periodontal instrumentation, blinding was not possible for patients 
nor operators. It was assumed patients were aware of instrumentation technique 
received – this is due to descriptions of interventions being provided during 
recruitment and consent discussions for relevant studies. This could potentially 
lead to performance bias as patients receiving certain treatments may alter 
their compliance or self-performed oral hygiene if they have greater faith in a 
specific intervention. Observation bias may also be present due to lack of 
operator/examiner blinding. However, these limitations may be argued to be 
within all interventional periodontal research to varying degrees.  
 
Non-statistically significant results must be treated with caution in the context 
of the current study. Such results may mean there is no difference in the wider 
population with regards to the various measures comparing hand, ultrasonic and 
combination instrumentation or alternatively, the sample size may not be large 
enough to show any differences as statistically significant. The current study was 
not appropriately powered to detect changes in clinical parameters, so inferring 
strong conclusions from such data is ill advised. Nevertheless, data serve as an 
interesting hypothesis creation tool for future studies.  The outline of a potential 
ideal future study design, addressing such sample size issues, is presented (Table 
6-1). 
 
Costings discussed were gained from a local NHS material acquisition portal and 
thus may vary according to health board and general dental practice. No 
consideration was made of the salary/wages of staff involved in the processing 
or sharpening of relevant instruments – this may further affect the result. 
Monetary values presented within the current study serve as an indication of 
potential costings, not an absolute representation. No consideration was made 
regarding the purchase cost of an ultrasonic base unit itself – these units have 
significant cost implications and would affect results, this is discussed in Chapter 
4. This factor was discounted in the current study as ultrasonic base units were 
readily available within the NHS Dental Hospital environment studied. The 
services of a health economist and the undertaking of a formal cost-
effectiveness analysis would prove valuable in fully exploring cost effectiveness 
of periodontal therapy in further detail. Given the high prevalence of severe 
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periodontitis that requires specialist treatment, there is clear merit in further 
more rigourous cost effectiveness analysis. 
 
Data regarding patient reported outcomes would ideally also include a form of 
validated scale for assessment such as the OHIP-14 scale. This has seven 
domains: functional limitation, physical discomfort, psychological discomfort, 
physical disability, psychological disability, social disability, and handicap 
(Slade, 1997). OHIP-14 is a shortened form of the original OHIP-49 and its 
reliability was demonstrated to be high (Cronbach’s coefficient alpha = 0.88 
(Slade, 1997)) and has been validated through assessment of associations with 
‘sociodemographic’ and ‘clinical oral status’ variables and shown to reliably 
correlate periodontal status with quality of life (Ng and Leung, 2006). Patient 
reported success is another technique for assessing patient reported outcomes in 
periodontology however this has been demonstrated to often be contrary to 
findings of clinical parameters of success and thus unreliable (Liu et al., 2010, 
Gilbert and Nuttall, 1999). Using a validated measure of patient reported 
outcome such as OHIP-14 would likely have led to a more robust data set and 
higher yield of meaningful findings in patient reported outcomes – this would 
have increased burden on the patients in the study.  
 
This study benefitted from a similar number of included patients for each 
treatment group (compared to other studies investigating clinical outcomes in 
non-surgical periodontal therapy (Ioannou et al., 2009, Loggner et al., 2009, 
Quirynen et al., 2006, Meulman et al., 2013)), resulting in tangible outcome 
data for a variety of clinical, systemic and patient-centred outcome parameters. 
The studies from which the current study gained data (randomised controlled 
trial and cohort study) were both well designed, implemented and at relatively 
low risk of bias. This would suggest data, at least in isolation, are reliable.  
 
The ability to compare exclusive interventions (hand or ultrasonic) to ‘treatment 
as usual’ using the comparator arm (combination) improved the current study’s 
external validity as this third arm is likely the most relatable to both general and 
specialist dental practice – the environments where the majority of periodontal 
disease is presumably treated in the United Kingdom.  
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The inclusion of patient centred outcomes assists in the consideration of 
periodontal treatment as a holistic treatment approach. Reassuringly, results 
confirm the satisfaction of patients with such treatment. 
 
Finally, this study also discussed a subject of particular interest in the 
contemporary periodontology literature – systemic inflammation following 
periodontal treatment. The results shown within the randomised clinical trial 
data section are of significance as results suggest equivalence of hand and 
ultrasonic instrumentation in provoking a systemic inflammatory response.  
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6.2 Conclusions 
6.2.1  Clinical  
• Periodontal treatment provided using exclusively hand instruments, 
exclusively ultrasonic instruments or a combination of these methods 
yields a comparable outcome in clinical parameters of periodontal 
disease.  
• Ultrasonic instrumentation takes less time to complete treatment than 
hand instrumentation. 
6.2.2  Systemic Inflammation  
• The systemic inflammatory response to full mouth debridement, 
measured at 24 hours following completion of treatment, is similar 
following hand or ultrasonic debridement.  
• The systemic inflammatory response, measured at 90 days following 
completion of treatment, is similar between all three instrumentation 
approaches. 
6.2.3  Economic  
• Periodontal treatment provided using a single instrumentation approach is 
less costly than using a combined instrumentation approach. 
• Periodontal treatment delivered by a ‘full mouth in 24 hours’ approach 
was associated with fewer episodes of expenditure, compared to a 
‘quadrant by quadrant’ approach. 
• Ultrasonic instrumentation was associated with the highest initial 
procurement cost however had the lowest maintenance and processing 
costs, and was associated with faster treatment time, which may further 
offset initial purchase costs. 
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6.2.4  Patient-Reported  
• Patients were satisfied with the experience and outcome of both hand 
instrumentation and ultrasonic instrumentation. 
• Patients in both treatment groups commented on notable improvements 
in self-perceived oral health. 
• The only theme emerging of a negative experience relating to treatment 
was unpleasant noise. This finding occurred only in the hand 
instrumentation group. 
• Some patients in both treatment groups commented on difficulties in 
accessing the research clinic. 
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